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1
Introduction
1.1 Gasotransmitter: An efficient family of messenger
molecules
Gasotransmitter represent a class of gaseous molecules that are endogenously generated and
involved in a variety of cell signaling mechanisms [Wang, 2014]. In contrast to classic messenger
molecules, e.g., neurotransmitters or hormones [Mustafa et al., 2009], gasotransmitters benefit
from their membrane permeability and fast diffusion properties. Due to these properties gaso-
transmitters are present in all organs where they affect cell metabolism in a more immediate
manner. Recent research has illuminated the potential of gasotransmitters and the significance
of their signaling network [Mann and Motterlini, 2007]. This has opened up new avenues and
perspectives of these molecules and paved the way for possible clinical applications. NO, CO and
H2S, are currently forming the family of gasotransmitters, as these molecules share common
features and fulfill the criteria for being a gasotransmitter [Wang, 2002, 2014]. They all share
commonalities in terms of reaction with haemoglobin, inhibition of cellular respiration presumably
via cytochrome c oxidase, vasodilatation and modulation of inflammatory responses. However,
the signaling mechanisms and pathways of each of the gasotransmitters vary in many aspects
[Szabo, 2007].
1.1.1 Nitric oxide
NO was the first identified gaseous signaling molecule [Wang, 2014], long before the term
’gasotransmitter’ was introduced in the year 2002 [Wang, 2002]. First declared as noxious,
nitric oxide is now considered an essential molecule in living organisms as research in this field
progressed [Alberto and Motterlini, 2007]. NO is endogenously generated by the enzyme NO
synthase (NOS) using L-arginine as the main substrate. There are three isoforms of this enzyme,
the most significant being the widespread inducible NO synthase (iNOS). The dominant biological
effect of nitric oxide is activation of soluble guanylyl cyclase (sGC) leading to the generation
of cGMP, which subsequently feeds a variety of signaling pathways. The plethora of biological
effects conveyed by NO includes relaxation of smooth muscle cells, inhibition of smooth muscle
cell growth, and preventing of platelet aggregation [McDonald and Murad, 1996; Moncada
and Higgs, 1991; Moncada et al., 1991; Murad, 1994]. Unveiling of these biological properties
unquestionably contributed to the design and implementation of NO based pharmaceuticals, today
used in the acute treatment of angina pectoris (glyceryl trinitrate) or hypertensive emergency
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(sodium nitroprusside). To underline the importance of the gasotransmitter nitric oxide, the
scientists who described the physiological function of NO were awarded the Nobel Prize in
Medicine 1998.
1.1.2 Hydrogen sulfide
The latest member of the gasotransmitter family is H2S [Wang, 2002]. This gaseous molecule is
endogenously produced in various mammalian cells by cystathionine β-synthase and cystathionine
γ-lyase from the substrate L-cysteine. These enzymes are mainly expressed in the nervous system,
liver, kidney and smooth muscle cells [Szabo, 2007]. Previously published in vivo data indicates
that H2S might have beneficial effects in terms of cytoprotection [Pan et al., 2006], adhesion of
neutrophils [Fiorucci et al., 2005; Zanardo et al., 2006], modulation of inflammatory response
[Sodha et al., 2009; Sodha and Sellke, 2015] and myocardial ischemia-reperfusion [Johansen
et al., 2006].
More recently, growing interest evolved in the research of H2S [Wang, 2014], including the design
of H2S-releasing compounds [Powell et al., 2018]. Interestingly, an intravenous H2S-related
compound entered a phase I trial for safety and tolerability [Szabo, 2007; Toombs et al., 2010],
although an intended phase II trial was terminated. There is still a need to further evaluate the
biological effects and signaling mechanisms since H2S can be very noxious at higher concentrations
[Szabo, 2007].
1.1.3 Carbon monoxide: Poisonous yet promising?
The third member of the group of gasotransmitter is carbon monoxide, which is endogenously
produced during physiological degradation of haem in mammalian cells [Rochette et al., 2013].
Responsible for the catabolism of haem are haem oxygenase (HO) enzymes [Sjostrand, 1951,
1952b], which cleave haem to biliverdin, carbon monoxide and ferrous iron (Fe2+) [Bauer and
Pannen, 2009; Coburn, 1970; Coburn et al., 1963; Sjostrand, 1952a; Tenhunen et al., 1968].
Subsequently, the ferrous iron is sequestered by ferritin until further usage. Biliverdin is converted
by biliverdin reductase into bilirubin, which is then excreted. The released carbon monoxide has
a high affinity for haem-containing proteins, both intracellular and extracellular. Ultimately, CO
diffuses, binds to haemoglobin and is exhaled through the lungs.
In a homeostatic state, the colorless and odorless gas is generated only in small amounts [Gullotta
et al., 2012]. The physiological production of CO can be quantified at a rate of about 16 µmol/h
per human body [Heinemann et al., 2014]. In comparison to NO, carbon monoxide is inert and
has a much longer half-life [Johnson et al., 1999; Rochette et al., 2013]. NO is highly reactive in
oxidative conditions leading to formation of peroxynitrite, which may aggravate inflammatory
and oxidative stress [Pacher et al., 2007; Wagener et al., 2003],
At elevated concentrations, however, CO is considered to be highly toxic to living organisms. This
intoxication is mainly caused by (prolonged) exposure to environmentally generated, exogenous
CO [Wu and Wang, 2005]. Compared to O2, carbon monoxide has a 200-times higher affinity
to bind to haemoglobin. The resulting carboxyhaemoglobin diminishes the blood capacity to
transport oxygen [Heinemann et al., 2014]. Interestingly, this may not be the major cause for
the toxicity of CO in living organisms. The toxic effect is most likely the increase of intracellular
CO concentration and tissue accumulation, leading to disturbance of mitochondrial function and
impairment of cellular respiration [Schatzschneider, 2015].
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Despite the noxious effect of high amounts of carbon monoxide, low concentrations of CO
mediate essential physiological functions. This ambivalence of CO was demonstrated for the
first time by data published by Marks et al. and others, that showed vasodilatative effects for
endogenous carbon monoxide [Marks et al., 1991; Motterlini et al., 1998; Suematsu et al., 1995,
1994; Wang et al., 1997]. In recent years, the ambiguous property of CO as a key factor in
cellular physiology and pathophysiology has been further delineated, as biological effects mediated
by endogenous CO can be mimicked by application of the exogenous equivalents. However, the
research of CO lags approximately 25 years behind when compared to NO [Mann and Motterlini,
2007].
1.2 The haem oxygenase system
In the catabolism of haem and endogenous production of CO, haem oxygenases are the rate-
limiting enzymes [Wagener et al., 2003]. These enzymes are highly conserved [Wagener et al.,
2003], and consist of three isoforms [Maines, 1997; McCoubrey et al., 1997]. HO-2 and HO-3
are constitutively expressed, whereas HO-1 is the inducible isoform, the expression of which differs
highly in different cell types [Morse and Choi, 2002]. Haem oxygenase-1 is mainly upregulated
under oxidative conditions or by redox active agents [Applegate et al., 1991; Otterbein et al.,
2000; Otterbein and Choi, 2000]. Previous studies identified various beneficial characteristics for
HO-1 in terms of cytoprotection and apoptosis [Inguaggiato et al., 2001; Otterbein et al., 1999;
Yang et al., 1999] as well as immunomodulation [Ke et al., 2002]. The beneficial properties of
HO-1 during oxidative stress and inflammation are believed to be mediated via the byproducts of
haem degradation, i.e., CO and bilirubin [Mustafa et al., 2009; Ryter and Choi, 2009].
1.3 Application of exogenous carbon monoxide
Initially CO has been used for in vitro and in vivo studies mainly in its gaseous form, i.e., either
by CO inhalation or by making use of CO gassed buffer solutions.
In vitro, carbon monoxide demonstrates cytoprotective and anti-proliferative properties [Brouard
et al., 2000; Sarady et al., 2002]. In terms of inflammation, CO appears to diminish pro-
inflammatory cytokines and to induce anti-inflammatory cytokines [Otterbein et al., 2000].
CO-enriched preservation solution seems to inhibit intimal hyperplasia [Nakao et al., 2011] and
reduces reperfusion injury for lung grafts [Kohmoto et al., 2008], the intestines [Nakao et al.,
2006] and kidney grafts [Nakao et al., 2008] of rats.
The administration of CO via inhalation has been extensively explored in vivo. In this concept,
delivery of CO to tissues occurs via the formation of carboxyhaemoglobin. Various studies have
demonstrated the therapeutic potential of this approach in a variety of models. Inhalation of CO
alleviates symptoms of pulmonary hypertension in mice [Zuckerbraun et al., 2006]. In rat models,
CO ameliorates reperfusion injury in kidney [Neto et al., 2004], lung [Kohmoto et al., 2006; Song
et al., 2003] and heart [Nakao et al., 2010]. Beneficial effects of CO inhalation were also shown
in cardiac transplantation models and arteriosclerosis [Otterbein et al., 2003b; Sato et al., 2001],
possibly mediated via modulation of cytokine expression resulting in anti-inflammatory effects
[Otterbein et al., 2000].
Several clinical trials administering CO via inhalation are currently ongoing (www.clinicaltrials.gov,
#NCT02425579, #NCT00094406). Phase II clinical studies showed safe application of low
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dose CO inhalation and beneficial trends in patients with stable COPD [Bathoorn et al., 2007]
and in patients with idiopathic pulmonary fibrosis [Rosas et al., 2018], however no significance
was accomplished.
It is expected that in humans high concentrations of carbon monoxide may be required to achieve
therapeutic concentrations of inhaled CO in body tissues [Heinemann et al., 2014; Mayr et al.,
2005]. Indeed, this drawback impedes the implementation of CO inhalation into clinical praxis.
An increase in carboxyhaemoglobin levels beyond 14-15% [Motterlini and Otterbein, 2010] may
lead to a shift of the CO-equilibrium, giving rise to tissue accumulation of carbon monoxide. As
a consequence, this condition can lead to impairment of cell respiration and thus, cell damage, as
previously stated. To avoid this phenomenon, delivery devices for a safe and monitored inhalation
of carbon monoxide have been invented recently [Motterlini and Otterbein, 2010]. It remains an
open question, whether or not these devices are suitable for this purpose and if parameters can
be established to control actual CO levels inside living organisms. Carbon monoxide needs to be
delivered in a controllable and ideally tissue-specific manner to prevent adverse drug reactions.
1.4 CO-releasing molecules: Principles of design
The chemical property of carbon monoxide to interact with transition metals has led to the
design of molecules that can release CO in a more controllable manner to circumvent the adverse
effects of CO inhalation. In fact, these so-called transition metal carbonyls are the basis for the
design of the majority of CO-releasing molecules (CORMs). Whereas inhalation of CO has been
the leading concept of administration in the early years, CO based therapeutic studies led to
a trend towards utilizing CORMs for CO administration. Also, the lack of therapeutic efficacy
of CO inhalation on inflammatory parameters in human volunteers [Mayr et al., 2005], and
contradictory data in rodent models has discouraged and challenged the route of administration
via CO inhalation [Stupfel and Bouley, 1970].
Motterlini et al. were the first to discover and identify this novel class of compounds [Motterlini
et al., 2002, 2005a]. Ever since, a great variety of CORMs have been designed. This chapter
gives a summary of the most important CO-releasing molecules. Generally, the structural design
of CORMs can be distinguished into two parts. The core of the compounds has been termed
CORM sphere, whereas the outer part has been labeled drug sphere. The inner part describes
the number of CO molecules bound to the metal and its release kinetics. The outer part of
the compounds characterizes the pharmaceutical profile [Romao et al., 2012; Schatzschneider,
2015]. There are large variations between the chemical properties, rates of CO release, and
release mechanisms of previously proposed CORMs [Motterlini et al., 2005a; Romao et al., 2012;
Zobi, 2013]. The mechanisms of release can either be by spontaneous dissociation of carbon
monoxide after dissolving in aqueous solutions, or by activation via chemical or physical stimuli
[Motterlini R, 2002; Niesel et al., 2008; Pfeiffer et al., 2009; Rimmer et al., 2010; Schatzschneider,
2010, 2011]. The metalcarbonyl complexes CORM-1 and CORM-2 were the first CORMs,
and soluble in DMSO. Both the manganese-containing CORM-1 and the ruthenium-containing
CORM-2 were shown to have vasoactive properties [Motterlini et al., 2002]. The water-soluble
CORM-3 and CORM-A1 liberate carbon monoxide once in contact with physiological solutions
[Foresti et al., 2008]. The ruthenium complex CORM-3 shows a rapid CO release, whereas the
CORM-A1 possesses a slow rate of CO liberation [Alberto and Motterlini, 2007]. The sodium
boranocarbonate CORM-A1 (not being a transition metal complex) shows beneficial effects
in terms of vasodilatation [Motterlini et al., 2005b], and cytoprotection [Babu et al., 2015a].
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The CO-releasing molecule that has been studied most intensively and is most widely used, is
CORM-3. This molecule possesses vasoactive properties [Foresti et al., 2004], antinociceptive
effects [Hervera et al., 2013], anti-inflammatory [Bergstraesser et al., 2012; Song et al., 2009] as
well as immunomodulatory properties [Masini et al., 2008; Vadori et al., 2009; Yabluchanskiy et al.,
2012]. In addition, CORM-3 may provide protection against vascular dysfunction [Mizuguchi
et al., 2010; Song et al., 2010] and oxidative damage [Mizuguchi et al., 2010; Motterlini et al.,
2012].
In recent years, various photoactivated CO-releasing molecules were designed. In most cases,
these so-called photoCORMs contain transition metals and liberate CO when stimulated with
UV or visible light [Niesel et al., 2008; Rimmer et al., 2012, 2010]. For these CORMs, topical
application might be a promising clinical application route, although further research needs to
be performed [Gonzales and Mascharak, 2014; Schatzschneider, 2015]. An interesting property
of CORMs in general is, that they do not have a significant impact on the generation of
carboxyhaemoglobin; this has been demonstrated by various in vivo studies [Motterlini and
Otterbein, 2010].
In summary, the different CORMs possess diverse biochemical properties in terms of stability,
pharmacokinetic and composition. The outstanding quality of transition metal carbonyls appears
to be the possibility to modify the composition or ligands leading to alternation of chemical
properties and pharmacokinetic, i.e., the drug sphere, as desired [Schatzschneider, 2015]. How-
ever, the issue of tissue specificity remains with CO inhalation and the aforementioned CORMs.
Additionally, it has to be stated that the latter deliver CO to tissue via passive diffusion. Therefore,
it is assumed that higher concentrations are required to achieve effective intracellular levels of
carbon monoxide when compared to direct administration of intracellular CO.
1.5 Enzyme-triggered CO-releasing molecules
Enzyme-triggered CO-releasing molecules (ET-CORMs) represent a group of CORMs that
use enzymatic cleavage of chemical bonds to release CO. Due to their enzyme specificity, this
class of CORMs promise CO delivery with high tissue specificity. The best-studied ET-CORMs
are those that are releasing CO intracellularly through the activity of esterase. ET-CORMs
are acyloxybutadiene tricarbonyl iron complexes consisting of a mother compound, i.e., 2-
cyclohexenone and 1,3-cyclohexanedione, and a type of dienylester ligands at varying positions
(Fig. 1.1).
Romanski et al. previously showed, that these primarily stable compounds are cleaved only in
an esterase dependent manner [Romanski et al., 2012, 2011a, 2013]. Once the compound has
entered the cell, intracellular esterases cleave the ester functionality. Subsequent spontaneous
oxidative decomposition of the labile enol complex leads to the release of the mother compound,
one molecule of ferric iron (Fe3+), and three molecules of carbon monoxide (Fig. 1.2) [Romanski
et al., 2012].
ET-CORMs are capable of protecting cells during hypothermic preservation and inhibiting VCAM-
1 expression on endothelial and epithelial cells upon TNF-α stimulation. In addition, they induce
HO-1 already at low concentrations. At high concentrations and depending on their structure they
may have a cytotoxic effect. Likewise, the biological properties of ET-CORMs strongly depend
on their chemical structure. Independent of the concentrations, the biological properties of
ET-CORMs depend on both the type and position of the ester substituent, as well as the mother
compound from which they are derived. ET-CORMs with an ester substituent at the outer
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position generally display biological effects (HO-1 induction, VCAM-1 inhibition, toxicity) at lower
concentrations compared to ET-CORMs with a substituent at the inner position. The efficacy
of ET-CORMs to mediate biological effects decreases with increasing length or complexity of
the ester substituent [Romanski et al., 2013; Stamellou, Storz et al., 2014].
Additionally, cell-specific differences in biological activity of ET-CORMs were observed during
experiments in RAW267.4 cells, human umbilical vein endothelial cells (HUVEC) and renal proximal
tubular epithelial cells (PTEC) [Romanski et al., 2012, 2013]. For instance, the cytotoxic effect
of ET-CORMs was more pronounced in HUVEC when compared to PTEC [Romanski et al.,
2013]. This effect suggests that PTEC and HUVEC may not have a similar spectrum of esterase
enzymes. Depending on the presence of certain esterase enzymes, ET-CORMs may be hydrolysed
to release CO intracellularly. ! !
   !
!
C15H31 
! ! !
C15H31 
!
!!
rac-1 rac-2 rac-3 
rac-4 rac-5 rac-6 
rac-7 rac-8 
Figure 1.1: Exemplification of ET-CORMs: Exemplification of ET-CORMs showing 2-cyclohexenone derived
compounds with the ester functionality at the inner position (top left panel), outer position (bottom left panel) and
1,3-cyclohexanedione derived compounds (panel to the right). Additionally, the various ligands (acetate, pivalate
and palmitate) are depicted (own illustration, adapted from Romanski et al. (2013)).
!
R 
Xxxx Fe (CO)3 
!
R 
Xxxx Fe (CO)3 
 
 
OH 
!
hydrolysis oxidation  
3 CO 
Fe 
R 
Figure 1.2: Decomposition of ET-CORMs: Decomposition of ET-CORMs (own illustration, adapted from
Romanski et al. (2012)).
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1.6 Aims of this dissertation
In this work selected ET-CORMs and their properties in terms of cytotoxicity and anti-inflammation
in endothelial cells (HUVEC) are investigated to address the question whether this novel class of
CORMs may hold advantages over previous forms of CO application. It is examined to what
extent variances in cellular uptake or CO release itself are responsible for the characteristic
biological activity amongst ET-CORMs and how structural alterations influence these properties.
An analysis is conducted to explore whether particularly carbon monoxide mediates the biological
effects of these compounds, or whether all by-products of intracellular cleaved ET-CORMs
contribute to it. More specifically, the study investigates if cytotoxicity is mediated by release
of CO leading to inhibition of cell respiration, or by the concomitant release and potential
accumulation of iron. For this analysis, the two 2-cyclohexenone derived ET-CORMs, i.e., rac-1
and rac-4 were selected, as they only differ with respect to the position of the ester functionality.
In addition, this work examines the effect of long-term treatment with ET-CORMs on VCAM-1
inhibition. This aspect is studied based on two types of ET-CORMs: The first one being derived
from 2-cyclohexenone (rac-1), the second one being derived from 1,3-cyclohexanedione (rac-8).
Additionally it is studied, if and how these ET-CORMs influence the activation of the transcription
factors involved in the regulation of VCAM-1 and HO-1 expression.
Finally, the relevance of structural alterations on biological properties of ET-CORMs was assessed
based on enantiomeric compounds. This is motivated by the fact that ET-CORM enantiomers
possess the same mother compound and carry the same ester functionality at the same position
but differ in the orientation of their functional groups being either in a trans or cis orientation.
7
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Materials and Methods
2.1 Consumable materials
The following subsection lists consumables, reagents, and analysis kits used in this work.
2.1.1 Chemicals, mediums and reagents
Chemical Manufacturer Catalogue number
Acrylamide mix 40% Sigma-Aldrich, St. Louis, USA 01708
APS (10%) Sigma-Aldrich, St. Louis, USA A3678
Chloroform Merck Life Science, Darmstadt,
Germany
1070242500
Coomassie Protein Assay Reagent Thermo Fisher Scientific,
Waltham, MA, USA
23200
Bovine serum albumin SERVA, Heidelberg, Germany 11920.06
Deferoxamine Sigma-Aldrich, St. Louis, USA D9533-1G
DEPC-treated water Thermo Fisher Scientific, AM9915G
DMSO Sigma-Aldrich, St. Louis, USA D5879 100 ml
DNase I Amplification Grade Thermo Fisher Scientific, 18068015
Waltham, MA, USA
2,2’-DPD Sigma, Taufkirchen, Germany D216305
DTT Sigma, Taufkirchen, Germany 43819
EDTA solution Sigma-Aldrich, St. Louis, USA E7889
Endothelial cell growth medium,
500 ml
Provitro, Berlin, Germany 2011101
Ethanol Thermo Fisher Scientific,
Waltham, MA, USA
9200-1
Ethidium bromide Sigma, Taufkirchen, Germany E7637
FCS Gold PAA, Pasching, Austria A15-151
Gelatine Sigma, Taufkirchen, Germany G7765
Glycine (>99%) Carl Roth, Karlsruhe, Germany 3908.2
HCl (1 mol/L) Merck, Darmstadt, Germany 1.09057.1000
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HEPES Sigma, Taufkirchen, Germany H3375
Hexadimethrine bromide Sigma, Taufkirchen, Germany H9268
IMDM Medium, no phenol red Thermo Fisher Scientific, Waltham,
MA, USA
21056-023
Isopropanol Carl Roth, Karlsruhe, Germany 9866.6
Laemmli Sample Buffer 30 ml Bio-Rad Laboratories, München,
Germany
161-0737
β-mercaptoethanol Sigma-Aldrich, St. Louis, USA M7522
Methanol Carl Roth, Karlsruhe, Germany HN41.2
Milk powder Carl Roth, Karlsruhe, Germany T145.4
(blotting grade)
NaCl 0.9% 500 ml B. Braun, Melsungen, Germany 3570130
NaCl 5 M Thermo Fisher Scientific, Waltham,
MA, USA
24740-011
PageRuler Plus Prestained Protein
Ladder
Thermo Fisher Scientific, Waltham,
MA, USA
26619
PBS (Dulbecco) Thermo Fisher Scientific, Waltham,
MA, USA
14190-144
PBS (Dulbecco) 10x Sigma, Taufkirchen, Germany D1408
Penicillin/Streptomycin Sigma-Aldrich, St. Louis, USA P-0781
Phosphatase Inhibitor Cocktail 2 (5
ml)
Sigma-Aldrich, St. Louis, USA P-5726
Protease Inhibitor Cocktail Tablets,
EDTA-free (25 tbl.)
Roche Diagnostics, Mannheim,
Germany
11836170001
SDS Sigma-Aldrich, St. Louis, USA 71725
Sodium deoxycholate Sigma, Taufkirchen, Germany D6750
TBS (10x) Carl Roth, Karlsruhe, Germany 1060.1
TEMED Sigma-Aldrich, St. Louis, USA T9281 - 25 ml
Tetrahydrofuran Merck, Darmstadt, Germany 109731
Thiazolyl Blue Tetrazolium Bromide
Reagent (MTT)
Sigma-Aldrich, St. Louis, USA M2128-5G
TGS buffer for SDS-PAGE Bio-Rad Laboratories 161-0732
(25 mM Tris/ 192 mM Glycine/
0.1% SDS; pH 8.3) (10x)
TNF-α R&D Systems, Wiesbaden, Germany 210-TA
(recombinant human)
Tris base Sigma, Taufkirchen, Germany T1503
Tris-HCl Buffer 0.5 M Bio-Rad Laboratories 161-0799
(pH 6.8)
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Tris-HCl Buffer 1.5 M Bio-Rad Laboratories 161-0798
(pH 8.8)
Tris-HCl Buffer 1 M (pH 7.5) Thermo Fisher Scientific, Waltham,
MA, USA
15567-027
Triton X-100 Sigma, Taufkirchen, Germany X100
TRIzol Reagent Thermo Fisher Scientific, Waltham,
MA, USA
15596-018
Trypsin LE Express Thermo Fisher Scientific, Waltham,
MA, USA
12604-021
TWEEN-20 Sigma-Aldrich, St. Louis, USA P1379
Western Lightning Plus-ECL,
Enhanced Chemiluminescence
Subtrate
PerkinElmer Inc., Boston, MA, USA NEL 103001EA
Table 2.1: Chemicals, mediums and reagents.
2.1.2 Buffers and solutions
Buffer/Solution Composition
Blocking solution for WB 5% milk powder dissolved in PBS
Inactivation solution 5% FCS in PBS
Loading buffer for SDS-PAGE 950 µl of Laemmli sample buffer + 50 µl β-
mercaptoethanol
Lysis buffer (ATP) 100 mM Tris, 4 mM EDTA, pH 7.75 in distilled
water
Lysis buffer I (protein isolation) 10 mM Tris-HCl, 150 mM NaCl, 5mM EDTA,
1% Triton X-100, 0.5% sodium deoxycholate
Lysis buffer II (protein isolation) 10 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA,
1% Triton X-100, 0.5% sodium deoxycholate
+ 1 µl DTT, 10 µl phosphatase inhibitor, 150
µl protease inhibitor
Protease Inhibitor 1 tablet of complete EDTA-free Protease In-
hibitor was dissolved in 1 ml of PBS
Running buffer for SDS-PAGE (1x) 100 ml of TGS (10x) + 900 ml distilled water
Solubilization solution (MTT) 10% SDS, 0.01 M HCl in distilled water
TBS (1x) 100 ml TBS (10x) + 900 ml distilled water
TBS-Tween 0.1% 1L TBS + 1 ml TWEEN-20
TBS-Tween 0.2% 1L TBS + 2 ml TWEEN-20
Thiazolyl Blue Tetrazolium Bromide Reagent
(MTT)
5 mg dissolved in 1 ml distilled water
Transfer buffer for blotting 750 ml distilled water, 150 ml Methanol, 100
ml TGS (10x)
Table 2.2: Prepared buffers and solutions.
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2.1.3 Kits
Name Manufacturer Catalogue number
ATP Bioluminescence Assay Kit
CLS II
Roche Diagnostics, Mannheim,
Germany
11699695001
Cignal Lenti NFκB/Nrf2/positive Qiagen, Düsseldorf, Germany CLS-013L,
control Reporter Assay (luc) CLS-2020L,
CLS-RCL
Cytotoxicity Detection Kit (LDH) Roche Diagnostics, Mannheim,
Germany
11644793001
Dual-Glo Luciferase Assay System Promega, Mannheim, Germany E2920
First strand cDNA synthesis Kit Roche Diagnostics, Mannheim,
Germany
11483188001
TaqMan universal PCR master
mix, no AmpErase UNG
Thermo Fisher Scientific,
Waltham, MA, USA
4324018
TaqMan gene expression assay:
hmox1
Thermo Fisher Scientific,
Waltham, MA, USA
Hs01110250_m1
TaqMan gene expression assay:
GAPDH
Thermo Fisher Scientific,
Waltham, MA, USA
Hs02758991_g1
Table 2.3: Kits.
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2.2 Devices
Name Manufacturer
ABI PRISM 7700 sequence detection system Applied biosystems
CASY TT cell counter Roche Diagnostics
Centrifuge Megafuge Heraeus Sepatech
Centrifuge Biofuge primo R Heraeus Sepatech
Centrifuge 5415 C Eppendorf
DNA Thermal Cycler Perkin Elmer
Dri-Block heater DB-2D Techne
Electrophoresis Power Supply EPS 301 General Electric
Fastblot B43, Core Life Sciences
electro-blotting apparatus
Fume hood Prutscher Laboratory Systems
Fusion SL Vilber Lourmat Peqlab
Hitachi U-2000 Spectrophotometer Hitachi, Scientific Istruments
Incubator (5% CO2, 37◦C) Hera cell 150 Heraeus Sepatech
Infinite M200, Microplate Reader Tecan Group Ltd
Laminar flow hood Heraeus Sepatech
Magnetic stirrer RCT basic Ika
Microscope DM IL Leica
Minigel-Twin for SDS-PAGE Biometra
Scale Kern 440-33 Kern
Scale Sartorius LP 620 S Sartorius
Shaker & Mixer Rotamax 120 Heidolph
Shaker & Mixer Polymax 1040 Heidolph
Sonifier W250 (ultrasonic homogenizer) Branson
Thermal Cycler 2720 Applied biosystems
Vortex-Genie 2 Scientific Industries
Water bath SW-21 Julabo
Table 2.4: Devices and equipment.
2.3 Enzyme-triggered CO-releasing molecules
2.3.1 Acyloxydiene complexes
Acyloxydiene-Fe(CO)3 complexes (ET-CORMs) were synthesized and assessed following the
protocols of Romanski et al. [Romanski et al., 2012, 2011a, 2013]. The release of CO triggered
by esterase was shown for all complexes using headspace gas chromatography (GC) and myoglobin
assay. The compounds rac-1 and rac-4 were derived from 2-cyclohexenone (L1), whilst rac-8
was derived from 1,3-cyclohexanedione (L2). The difference between rac-1 and rac-4 is the
position of the ester, being either at the inner (rac-1) or outer position (rac-4) of the enone
moiety. Both, rac-1 and rac-4, harbour an acetate moiety while rac-8 has a pivalate as ester
substituent at both the inner and outer position. To assess whether the biological activity of
ET-CORMs was mediated via release of carbon monoxide or via the organic byproducts after
13
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!
Figure 2.1: ET-CORMs: Chemical structure of the compounds used in the study. The two 2-cyclohexenone
derived ET-CORMs, i.e., rac-1 and rac-4, and the one derived from 1,3-cyclohexanedione (rac-8) are depicted.!
L1 
(rac-1 and rac-4)  
L2                                   L3 
                    (rac-8)                            
Figure 2.2: Enones: The corresponding hydrolysis products of ET-CORMs resulting from hydrolysis/oxidative
desintegration of rac-1 and rac-4 (L1) and of rac-8 (L2 and L3) were used to dissect if the hydrolysis products
are partly underlying the biological activity of ET-CORMs.
ET-CORM decomposition, the parent compounds of the ET-CORMs used were included in this
study. These are 2-cyclohexenone (L1), 1,3-cyclohexanedione (L2) and composite L3 formally
derived from monohydrolysis and decomplexation of rac-8. For the experiments, ET-CORMs
and their mother compounds were dissolved in DMSO at a concentration of 1 mM and stored
at -20◦C until usage. The chemical structures and annotations of the compounds are shown in
Figs. 2.1 and 2.2.
2.3.2 Cyclodextrin encapsulated ET-CORMs
The compounds rac-1 and rac-4 were additionally used as randomly methylated-beta-cyclodextrin
(RAMEB) complexes in cell culture experiments, to assess if the difference in their bioactivity was
due to a differential cellular uptake of these ET-CORMs. For this purpose, 2.4 mg (8.75 µmol)
of rac-1 or 2.8 mg (10 µmol) rac-4 were added to a water solution of 41.25 mM (or 40 mM,
respectively) of RAMEB. The chemical formation of the complexes was achieved by treating
the samples in an ultrasonic bath for 30 minutes at 80◦C. To assess release of carbon monoxide
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from ET-CORM/RAMEB complexes CO Probe 1 (COP-1) was used. For this purpose, COP-1
(10 µM), the ET-CORM/RAMEB complexes (RAMEB@rac-1 and RAMEB@rac-4) (each 100
µM) and pig liver esterase (3 U/ml) were incubated in 96-well plates for various time points. Pig
liver esterase was substituted for HUVEC cell lysates (10 µg/ml) as an esterase source in some
experiments. The cell lysates were prepared by repeated cycles of freeze-thawing in PBS. In all
experiments controls were included by omitting pig liver esterase or cell lysate. The fluorescence
intensity was measured at an excitation wavelength of 475 nm and an emission wavelength of
510 nm. Fluorescence intensity of the controls was subtracted for each condition.
2.3.3 ET-CORMs as enantiomers
To evaluate the biological activity in relation to the structure of the compound in a more detailed
manner, and to furthermore optimize the chemical substance, enantiomers of ET-CORMs were
synthesized [Romanski, 2013]. The geometric isomers of ET-CORMs used in this thesis are
divided accordingly into two groups. The first group comprises trans-enantiomers, i.e., Stro
786-A and Stro 790-A, and the second group consists of cis-enantiomers, i.e., Stro 786-C and
Stro 790-C. However, there are also structural differences within one group. Compound Stro
786-C harbours the substituent groups facing upwards, whereas substituent groups of Stro 790-C
facing downwards when comparing with the plane. For experiments, ET-CORM enantiomers
were dissolved in DMSO at a concentration of 1 mM and stored at -20◦C until usage.
OAc OAc 
Fe(CO)3 Fe(CO)3 
Stro 786-A Stro 790-A 
Figure 2.3: Trans-enantiomers.
OAc OAc 
Fe(CO)3 Fe(CO)3 
Stro 786-C Stro 790-C 
Figure 2.4: Cis-enantiomers.
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2.4 Experimental Methods
2.4.1 Cell culture
Human umbilical vein endothelial cells (HUVEC) were purchased from Promo Cell, Heidelberg,
Germany. HUVEC were cultured in basal endothelial medium supplemented with 10% FCS,
essential growth factors and antibiotics (Penicillin/Streptomycin) in T75 flasks in a 5% CO2-
humidified atmosphere at 37◦C until confluence.
For cell passaging, cells were washed with PBS and trypsinized for 5 minutes at 37◦C. Inactivation
solution (5% FCS in PBS) was added and cells were harvested. Flasks were washed with PBS
to collect remaining cells. Cell detachment of HUVEC from the flask was monitored using a
microscope. Cell suspension was centrifuged for 5 minutes at 1200 rpm at room temperature.
After aspirating supernatant, cell pellet was resuspended in appropriate HUVEC medium and
seeded into appropriate flasks or wells (passaging in a relation of 1:3). Flasks and wells were
prepared for seeding with filtered 1% gelatine for 15-30 minutes at RT. Experiments with HUVEC
were conducted on cells in passages 4-6 at approximately 80-90% confluence.
2.4.2 Evaluation of intracellular proteins
Protein isolation
After cells were stimulated with TNF-α (10 ng/ml) and different concentrations of ET-CORMs
depending on the experiment, proteins were isolated for further investigations. Prepared In-
activation solution, PBS and Trypsin were stored in water bath at 37◦C. Cell extracts were
made from trypsinized HUVEC by resuspending the cell pellet in 50 µl of lysis buffer II (10 mM
Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% triton X-100 and 0.5% sodium deoxycholate, 1 µl of
freshly prepared DTT, 150 µl protease inhibitor and 10 µl phosphatase inhibitor). The lysate
was transferred into 1.5 ml Eppendorf tubes and incubated for 5 minutes on ice. Hereafter the
samples were centrifuged at 14000 rpm for 10 minutes at 4◦C. Supernatants were transferred
into new 1.5 ml Eppendorf tubes and stored at -20◦C until use.
Protein quantification
Total protein concentration of extracts was measured according to Bradford [Bradford, 1976].
Samples were diluted to 1:10 with NaCl 0.9% and 1 ml of Coomassie-Reagent was added to
each Eppendorf tube. After 10 minutes of incubation at RT optical density at 595 nm (OD595)
of the samples were measured by a spectrophotometer (Hitachi U-2000). Protein concentrations
were calculated based on a standard curve of known protein concentrations.
SDS-PAGE and Western blotting
For the polyacrylamide gel electrophoresis 10% SDS-gels were prepared. The running gel was
mixed according to Tab. 2.5 and immediately poured to assembled gel casting unit, leaving 2-3
cm space for the stacking gel. 500 µl of isopropanol was added to the casting unit to ensure
a straight boundary between running and stacking gel. After polymerisation isopropanol was
removed, the stacking gel prepared and poured on top of running gel. A comb with ten cavities
(capacity each 15-18 µl) was inserted in the stacking gel. After polymerisation of the gel, the
16
Chapter 2 Materials and Methods
Stacking gel Running gel
dH2O 3.6 ml 4.8 ml
Acrylamide mix 40% 620 µl 2.5 ml
Tris-HCl 1.5 M (pH 8.8) - 2.5 ml
Tris-HCl 0.5 M (pH 6.8) 630 µl -
SDS 10% 50 µl 100 µl
TEMED 5 µl 4 µl
APS 10% 50 µl 100 µl
Table 2.5: Composition of SDS-gel.
Antibody Manufacturer Catalogue number
Anti-β-actin Sigma, Taufkirchen, Germany A5441
(monoclonal, mouse)
Anti-GAPDH Abcam, Cambridge, USA ab9484
(monoclonal, mouse)
Anti-HO-1 Enzo, Lörrach, Germany ADI-SPA-896
(polyclonal, rabbit)
Anti-IκBα Santa Cruz Biotechnology, sc-371
(polyclonal, rabbit) Heidelberg, Germany
Anti-VCAM-1 Cell Signaling Technology, 12367S
(polyclonal, rabbit) Boston, USA
Secondary antibodies (conjugated
with horseradish peroxidase)
Santa Cruz Biotechnology,
Heidelberg, Germany
- goat anti-rabbit IgG-HRP sc-2004
- goat anti-mouse IgG-HRP sc-2005
Table 2.6: Antibodies for Western blotting.
casting unit was transferred to the electrophoresis chamber. Subsequently, the chamber was
filled with running buffer.
20 µg of protein extract (or otherwise specified) was mixed with loading buffer in the ratio 1:1.
Subsequently the samples were incubated for 5 minutes at 100◦C, followed by short centrifugation
and incubation for 5 minutes on ice. Electrophoresis was initiated using 80 mV for 20-30 minutes
for stacking of the samples, hereafter the gels were run at 130 mV for approximately 90 minutes.
After electrophoresis, proteins were transferred by semi-dry blotting to a PVDF western blotting
membrane (Roche Diagnostics) according to standard operating procedures. The membranes were
blocked in blocking buffer for 1 hour at RT on a shaker to prevent unspecific background staining.
Hereafter, blots were incubated overnight at 4◦C with polyclonal anti-VCAM-1 (dilution 1:1000),
polyclonal anti-IκBα (dilution 1:1000), polyclonal anti-HO-1 (dilution 1:1000), monoclonal anti-β-
actin antibody (dilution 1:5000) or anti-GAPDH antibody (dilution 1:5000) (all dilutions in blocking
buffer). The membranes were thoroughly washed in TBS-Tween 0.1% and then incubated for 1
hour at room temperature with the appropriate IgG-Horseradish peroxidase secondary antibody
in blocking buffer (dilution 1:2000, Tab. 2.6). Subsequently, the membranes were washed in
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TBS-Tween 0.1% 5 times for 5 minutes each. Protein bands were visualized by using enhanced
chemiluminescence substrate following the manufacturer’s instructions (PerkinElmer Inc., USA).
2.4.3 Cell toxicity
MTT Cell toxicity assay
HUVEC were cultured in 96-well plates until confluence. Subsequently, cells were treated with
different concentrations of rac-1, rac-4 either dissolved in DMSO or as RAMEB complexes,
as well as with ET-CORM enantiomers for the indicated time periods. In some experiments,
HUVEC were treated for 24 hours with serial dilutions of FeCl2 or FeCl3 or rac-4 (100 µM)
in the presence or absence of iron chelators deferoxamine (80 µM) or 2,2-DPD (100 µM).
Deferoxamine was added to the cells at the time of stimulation with ET-CORMs, whereas 100
µM 2,2’-DPD was used for 1 hour prior to stimulation. Assessment of cytotoxicity was performed
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. At the
indicated times, 10 µl of 5 mg/ml MTT reagent was added to each well generating a light yellow
solution, following incubation for 4 hours at 37◦C and in 5% CO2 atmosphere. Hereafter 100 µl
of solubilisation solution was added to each well to dissolve the purple formazan crystals and the
plates were incubated overnight at 37◦C, 5% CO2. Absorbance was measured the next day at
a wavelength of 550 nm with a reference wavelength 690 nm using Infinite M200 Microplate
reader. Cell viability was expressed as percentage of viable cells relative to the untreated cells.
All experimental conditions were tested in triplicates in at least 4 different experiments.
LDH Cytotoxicity assay
To assess the effects of ET-CORM enantiomers during cold preservation injury, the cytotoxicity
detection kit (LDH, Roche Diagnostics) was used. To this end, HUVEC were cultured in 24-well
plates until confluence. While adding ET-CORM enantiomers for stimulation, the medium was
changed to IMDM phenol free medium (without supplements) to avoid interactions of phenol
red with the LDH cytotoxicity kit. Subsequently, cells were placed on ice at 4◦C for 24 hours.
LDH was measured according to the manufacturer’s instructions. Absorbance was measured at
490 nm with 620 nm as reference wavelength. All experiments were tested in triplicates in 3
independent experiments.
2.4.4 Intracellular ATP Measurement
Intracellular ATP concentration was assessed by performing a bioluminescence assay (Roche
Diagnostics). HUVEC were cultured in 24-well plates until confluence. Subsequently, cells were
treated with different concentrations of rac-1 and rac-4 for a certain period of time (15 min, 60
min or 24 h depending on the specific experiment). Cells were washed twice in PBS. 200 µl of
lysis buffer (ATP) was added to each well and the 24-well plate was incubated for 10 minutes
at RT on a shaker. Cell lysates containing intracellular ATP were harvested and distributed
to cavities of a 96-well plate, 50 µl of samples per cavity. Subsequently, 50 µl of luciferase
from freshly prepared luciferase reagent (10 ml of ddH2O added to luciferase reagent, 5 minutes
incubation at 4◦C) was added to each well followed by immediate measurement of luminescence.
An ATP Standard was serial diluted from 16.5 mM × 10−5 until 16.5 mM × 10−11 and included
in each experiment. All experimental conditions were tested in triplicates in at least 3 different
experiments.
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2.4.5 Detection of intracellular CO-release
CO Probe 1 (COP-1), a reaction-based fluorescent substrate, was used to assess intracellular
release of CO and was synthesized as reported [Michel et al., 2012]. To catalyze ET-CORMs,
pig liver esterase (3 U/ml) or HUVEC cell lysates (10 µg/ml; prepared by freeze-thawing in
PBS) were incubated with 1 µl/ml (final concentration 10 µM) of COP-1 in the presence of
ET-CORMs (100 µM) in a 96-well plate at 37◦C for various time points. Controls were included
by omitting pig liver esterase or cell lysate. The fluorescence, based on Palladium-mediated
carbonylation, was measured at an emission wavelength of 510 nm and excitation wavelength of
475 nm. For each condition the fluorescence intensity of the controls was subtracted. In addition
to fluorescence measurement, confocal microscopy was used to visualize CO-release with COP-1.
2.4.6 Reporter assay
HUVEC were cultured in 96-well plates and transduced with commercially available lentiviral
particles containing an inducible NFκB or Nrf2 luciferase reporter (Qiagen, Germany). The
medium was removed from the cavities and 20 µl of Cignal lenti particles were added. Subsequently,
cell growth medium was added to each well, following incubation at 37◦C in an atmosphere of
5% CO2. For each condition, transduction efficiency was assessed with a constitutively expressed
luciferase construct. Two days after transduction, the medium was removed and cells were
stimulated with TNF-α (10 ng/ml) and/or different concentrations of ET-CORMs in triplicates
for 24 hours. Luciferase activity measurements were performed following the manufacturer’s
protocol (Promega, Germany). Dual-Glo Luciferase Reagent and Dual-Glo Stop & Glo Reagent
were prepared. 50 µl Dual-Glo Luciferase Reagent was added to each well, followed by incubation
of 10 minutes at RT. Firefly luminescence was measured. Subsequently, 50 µl Dual-Glo Stop &
Glo Reagent was added following incubation of 10 minutes at RT and measurement of renilla
luminescence. Inducible luciferase expression was normalized for constitutively expressed luciferase
to control differences in transduction efficiency. The data of 4 independent experiments are
expressed as mean fold increase ± standard deviation relative to the control.
2.4.7 Isolation of RNA and qPCR
To isolate total RNA from cultured HUVEC, cells were trypsinized and washed after 24 hours of
stimulation with rac-1 or rac-8. Each cell pellet was subsequently resolved with TRIzol Reagent
1 ml per 107 cells and incubated for 10 minutes at RT for complete dissociation of nucleoprotein
complexes. Hereafter 200 µl of Chloroform was added, shaken and incubated for 3 minutes at RT.
Samples were centrifuged at 12000 rcf and 4◦C for 15 minutes. The aqueous phase containing
total RNA, was transferred to fresh, RNase-free Eppendorf tubes and 0.5 ml of isopropanol
was added to precipitate the RNA. After centrifugation at 12000 rcf and 4◦C for 10 minutes,
pellets were washed twice with 1 ml ethanol 75%. After the final centrifugation at 7500 rcf for 5
minutes, the RNA pellets were air dried and dissolved in 20 µl of DEPC-treated water. RNA
concentration was measured with the Infinite M200 Microplate Reader and samples were stored
at -80◦C until further use.
To eliminate DNA from the samples, DNase treatment was performed prior to qPCR using the
DNase I Amplification Grade (Thermo Fisher Scientific). Samples were thawed at RT. DNase I
Reaction Buffer at a concentration of 10% of the sample volume and 1 µl of DNase I Amp Grade
(1 U/µl) were added. Subsequently, the solution was filled up to 10 µl with DEPC-treated water
followed by incubation for 15 minutes at RT. 1 µl of EDTA (25 mM) was added to inactivate
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the DNase and to avoid Mg2+-dependent hydrolysis of RNA. Eppendorf tubes were heated for
10 minutes at 65◦C and were immediately put on ice afterwards.
1 µg of total RNA was reverse transcribed into cDNA using the first strand cDNA synthesis kit
(Roche Diagnostics, Tab. 2.7). Components were mixed gently, following reverse transcriptase
reaction using Thermal Cycler 2720 (Applied biosystems) with the following setting:
- 10 minutes at 25◦C
- 60 minutes at 42◦C
- 5 minutes at 99◦C
- 5 minutes at 4◦C
cDNA was diluted in 20 µl DEPC-treated water and stored at -20◦C until usage. Samples were
evaluated in 1% agarose gel electrophoresis with supplement of ethidium bromide.
Component Volume (total 20 µl)
RNA sample (DNase treated) 1 µg
10x Reaction Buffer 2 µl
25 mM MgCl2 4 µl
Deoxynucleotide Mix 2 µl
Oligo-p(dT)15 Primer 2 µl
RNase Inhibitor 1 µl
AMV Reverse Transcriptase 0.8 µl
Table 2.7: First strand cDNA synthesis.
Real-time quantitative PCR was performed on an ABI PRISM 7700 sequence detection system
(Applied biosystems) using TaqMan universal PCR master mix, no AmpErase UNG. For the
quantification of gene expression of interest, TaqMan gene expression assays for HO-1 (hmox1)
and GAPDH were used (all Thermo Fisher Scientific, Tab. 2.3 ). Reaction mix was prepared
accordingly and samples were run under the following conditions:
1) Initial denaturation for 10 minutes at 95◦C, followed by
2) 40 cycles of
- denaturation for 15 seconds at 95◦C and
- annealing/extension for 1 minute at 60◦C.
The comparative cycle threshold method (∆∆CT method) was used to determine the levels of
gene expression in each sample. The levels of the target gene (hmox1) were referred to the
levels of the reference gene (GAPDH), whose expression is not influenced. The efficiency of the
PCR was assessed from the slopes of the standard curves and was found to be between 90%
and 100%. Linearity of the assay could be demonstrated by serial dilution of all standards and
cDNA. All samples were normalized for an equal expression of GAPDH.
Equation of the ∆∆CT method:
∆∆CT = ∆CT (treated) − ∆CT (control)
∆∆CT =
[
(Cttarget gene − Cttarget gene)treated − (Cttarget gene − Cttarget gene)control
]
2−∆∆CT = fold change due to treatment
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2.5 Statistical analysis
All data are expressed as the mean ± standard deviation unless otherwise specified. At least
three independent experiments were performed. Statistical significance was assessed by One-
way-ANOVA and student’s t-test. P-value of P < 0.05 was considered as significant. GraphPad
Prism (GraphPad Software, Inc., La Jolla, USA) was used for calculation of EC50 values and
curve fitting. Statistical analysis for the data of ET-CORMs was performed by Eleni Stamellou.
21
22
3
Results
3.1 ET-CORMs as enantiomers
Enantiomers describe the three-dimensional position of their substituent group. Stro 786-A and
Stro 790-A represent trans-enantiomers with the substituent group facing upwards (Stro 786-A)
or downwards (Stro 790-A), while Stro 786-C and Stro 790-C are the cis-enantiomers of the
same structure (Figs. 2.3 and 2.4). This study assessed if the two enantiomers of ET-CORMs
behave different with respect to the biological activity that was tested (toxicity, inhibition of
VCAM-1, induction of HO-1 and protection against cold inflicted injury of endothelial cells).
3.1.1 Cytotoxicity, VCAM-1 inhibition and HO-1 induction
Cytotoxicity in HUVEC cell cultures, measured after 24 hours of stimulation with the test
compounds, was consistently more pronounced for the cis-compounds, i.e., Stro 786-C and Stro
790-C, when compared to the trans-compounds (Stro 786-A and Stro 790-A) at concentrations
of 25 µM up to 100 µM (Fig. 3.1). Within the cis-compounds itself, Stro 790-C was more toxic
than Stro 786-C. These differences were not found for the trans-enantiomers Stro 786-A and
Stro 790-A. ET-CORM enantiomers can effectively inhibit TNF-α mediated VCAM-1 expression
as demonstrated by Western blotting (Fig. 3.2). Whereas the trans-enantiomers inhibit VCAM-1
expression at a concentration of 50 µM, for the cis-enantiomers a strong inhibition was noted
already at 25 µM. Hence, similar as mentioned for cytotoxicity, the cis-enantiomers seem to
be more effective than the trans-enantiomers, and within the cis-enantiomers, Stro 790-C
inhibits VCAM-1 much stronger than Stro 786-C when compared at a concentration of 25 µM.
Interestingly, Stro 790-C seems to inhibit VCAM-1 more effectively at a concentration of 25
µM in comparison to 50 µM of Stro 786-A and Stro 790-A. In addition to VCAM-1 inhibition,
this study assessed the ability of the enantiomers to induce HO-1 expression. Comparable to
VCAM-1 inhibition, cis-enantiomers (25 µM) induce HO-1 more effectively when compared to
trans-enantiomers (50 µM or 25 µM).
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Figure 3.1: Cytotoxicity of ET-CORM enantiomers: HUVEC were grown in a 96-well plate until confluence and
subsequently treated for 24 hours with different concentrations of ET-CORM enantiomers. MTT cytotoxicity
assays were performed as mentioned in the methods section. The data of a representative experiment are depicted.
The results are expressed as mean % of cell viability ± SD, relative to the untreated HUVEC. All conditions were
tested in triplicates in 3 different experiments.
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Figure 3.2: Inhibition of VCAM-1 and induction of HO-1 by ET-CORM enantiomers: HUVEC were grown in
24-well plates until confluence. To demonstrate whether ET-CORM enantiomers have an influence on VCAM-1
and HO-1 expression, cells were stimulated with TNF-α for 24 hours in the presence or absence of different
concentrations of ET-CORM enantiomers. VCAM-1 and HO-1 expression was assessed by Western blotting,
GAPDH was used as loading control. Data of a representative experiment are shown. At least 4 independent
experiments have been performed with essentially the same result.
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3.1.2 Cold preservation injury
As demonstrated by light microscopy and LDH release, ET-CORM enantiomers displayed
protection against cell damage occurring after 24 hours of cold preservation (at 4◦C) of HUVEC
(Figs. 3.3 and 3.4). At a concentration of 25 µM, the cis-enantiomers showed comparable
protective effects, which were more pronounced compared to the trans-enantiomers. Cell damage
and cell integrity evaluated by light microscopy prior to LDH detection clearly displayed a higher
tolerance to hypother-mia when HUVEC were treated with ET-CORM enantiomers (Fig. 3.4).
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Figure 3.3: LDH release during cold preservation by ET-CORM enantiomers: HUVEC were cultured in a 24-well
plate until confluence. Cells were stimulated with 25 µM of different ET-CORM enantiomers in IMDM phenol free
medium. Subsequently, cells were put on ice and stored at 4◦C for 24 hours. Supernatant was harvested and LDH
cytotoxicity detection kit (Roche Diagnostics) was used to assess the tolerance to hypothermia-associated cell
damage as described in the methods section. Untreated cells (medium) served as control. The data expressed as
mean LDH release ± SD of a representative experiment are depicted, ∗ P < 0.05, ∗∗ P < 0.01, ∗ ∗ ∗ P < 0.001.
All conditions were tested in triplicates in 3 independent experiments.
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Figure 3.4: Tolerance to hypothermia due to treatment with ET-CORM enantiomers: Microscope images showing
HUVEC after 24 hours of cold preservation. HUVEC were microscopically evaluated after 24 hours of cold
preservation at 4◦C in the presence or absence of ET-CORM enantiomers [25 µM]. HUVEC not treated with
ET-CORM enantiomers and cultured at 37◦C served as control. Original magnification: 10x.
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3.2 ET-CORMs
The following results have been published in Redox Biology (2014) 2:739-748 "Different design
of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in
biological activities in terms of toxicity and inflammation." by Stamellou E. and Storz D. as
equally contributing first authors. My contribution to this publication was the performance of
experiments, acquisition of data, illustration of figures, and drafting of the paper. The content
of this part is depicted in extended form.
3.2.1 CO release, toxicity and intracellular ATP concentrations
Although the 2-cyclohexenone derived ET-CORMs rac-1 and rac-4 (Fig. 2.1) display minor
structural differences, i.e., the position of the ester functionality, they strongly differ with respect
to cytotoxicity [Romanski et al., 2013]. Because cellular uptake of cyclodextrin-formulated
compounds predominantly depends on structural entities of the cyclodextrin polymer rather than
that of the compounds it encapsulates, rac-1 and rac-4 were prepared as such RAMEB@rac-1
and RAMEB@rac-4 respectively, to assess whether the differences in cytotoxicity were caused
by quantitative differences in cellular uptake or by spatiotemporal differences in CO release.
CO was still released from the cyclodextrin-formulated compounds, as demonstrated by a time-
dependent increase in fluorescence intensity when COP-1 was incubated with RAMEB@rac-1
and RAMEB@rac-4 in the presence of pig liver esterase or lysates of HUVEC as esterase source
(Fig. 3.5). CO release in this assay was significantly higher for RAMEB@rac-4 as compared to
RAMEB@rac-1 and was more pronounced when lysates from HUVEC were used. When HUVEC
were cultured for 24 hours with different concentrations of rac-1 and rac-4, either dissolved
in DMSO or used as cyclodextrin formulation, rac-4 was consistently more toxic compared to
rac-1 irrespective of the formulation (EC50 [µM] rac-1 vs. rac-4: 448.9 ± 50.23 vs. 8.2 ±
1.5, EC50 [µM] RAMEB@rac-1 vs. RAMEB@rac-4: 457.3 ± 8.23 vs. 7.22 ± 1.12) (Fig. 3.6).
Based on the notion that cellular uptake of the cyclodextrin-formulated RAMEB@rac-4 and
RAMEB@rac-1 is equal, the present data indicate that RAMEB@rac-4 is significantly more
toxic as a consequence of a higher CO release as compared to RAMEB@rac-1.
Cell toxicity was also observed when HUVEC were incubated with FeCl2 or FeCl3 (Fig. 3.7, top
graph), indicating a potential deleterious role for the concomitantly released iron upon ET-CORM
hydrolysis. However, EC50 values for rac-4 were significantly lower compared to FeCl2 or FeCl3
(EC50 FeCl3 vs. rac-4, ∼ 120 vs. 8.2 ± 1.5 [µM]) and were neither influenced by deferoxamine
(Fig. 3.7, bottom graph) nor by the more cell membrane permeable 2,2’-dipyridyl (2,2-DPD) iron
chelator (data not shown). Interestingly, intracellular ATP concentrations were slightly increased
at low concentrations of both rac-1 and rac-4, while at high concentrations intracellular ATP
strongly diminished in HUVEC that were treated with rac-4 but not with rac-1 (Fig. 3.8, top
graph). When 100 µM of rac-4 was added to HUVEC, ATP concentrations already diminished
within 15 minutes (Fig. 3.8, bottom graph).
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Figure 3.5: Release of CO by cyclodextrin formulated ET-CORMs: CO release from rac-1 and rac-4 in cyclodextrin
formulation RAMEB@rac-1 and RAMEB@rac-4 respectively was assessed by measuring COP-1 fluorescence
intensity. To this end, COP-1 (10 µM ), RAMEB@rac-1 and RAMEB@rac-4 (100 µM for both) and pig liver
esterase (3 U/ml) (top graph) or cell lysates from HUVEC (10 µg/ml) (bottom graph) were incubated in 96-well
plates for various time points. In all experiments controls were included by omitting pig liver esterase or cell lysate.
Fluorescence intensity of the controls was subtracted from the fluorescence intensity of each condition. The results
of 3 independent experiments are depicted as mean fluorescence intensity in arbitrary units ± SD, ∗ P < 0.05,
∗∗ P < 0.01.
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Figure 3.6: Cytotoxicity for rac-1, rac-4 and cyclodextrin encapsulated ET-CORMs: HUVEC were grown in
96-well plates until confluence and subsequently stimulated for 24 hours with different concentrations (0 µM to
200 µM) of rac-1, or rac-4 either dissolved in DMSO (top graph) or as cyclodextrin formulation RAMEB@rac-1
and RAMEB@rac-4 (bottom graph). Toxicity was assessed by MTT assay, each concentration was tested in
triplicate in all experiments. The results of 3 independent experiments are expressed as mean % of cell viability ±
SD, relative to the untreated HUVEC. The corresponding EC50 [µM] were: rac-1 vs. rac-4: 448.9 ± 50.23 vs. 8.2
± 1.5, EC50 [µM] RAMEB@rac-1 vs. RAMEB@rac-4: 457.3 ± 8.23 vs. 7.22 ± 1.12.
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Figure 3.7: Iron-mediated toxicity compared to rac-4 (with or without iron chelator): Serial dilutions of FeCl2
(open circles, dotted line) or FeCl3 (closed circles) and rac-4 (closed squares) were added to HUVEC grown in
96-well plates and toxicity was measured similar as described above (top graph). To test if iron-mediated toxicity
was abrogated in the presence of deferoxamine, cells were stimulated with 125 µM of FeCl2, FeCl3 or rac-4 in the
presence (filled bars) or absence (open bars) of deferoxamine (80 µM) (bottom graph). The plates were incubated
for 24 hours and cell viability was assessed by MTT assay as described. The results of 3 independent experiments
are expressed as mean % of cell viability ± SD, relative to the untreated HUVEC. ∗∗ P < 0.01.
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Figure 3.8: Effects on intracellular ATP-levels by rac-1 and rac-4: HUVEC were grown in 24-well plates until
confluence, treated with rac-4 or rac-1 for 24 hours. Subsequently intracellular ATP was measured (top graph). In
separate experiments, 50 µM of rac-4 was added to HUVEC and ATP was measured at 0, 15 and 60 minutes after
addition of ET-CORM (bottom graph). ATP was measured using an ATP-driven luciferase assay as described in
the methods section. The results of 4 independent experiments are expressed as mean relative light units (RLU) ±
SD. In all experiments each condition was tested in triplicates. ∗ P < 0.05, ∗∗ P < 0.01 vs. the untreated HUVEC.
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3.2.2 VCAM-1 inhibition and long term ET-CORM treatment
The previous study has revealed that rac-1 and rac-8 inhibit TNF-α mediated VCAM-1 expression
[Romanski et al., 2013]. Also rac-4 inhibits VCAM-1 at low non-toxic concentrations, i.e., [rac-4]
≤ 3 µM (Fig. 3.9). In this study, a more detailed analysis of VCAM-1 inhibition and cell toxicity
in long-term experiments is performed only for rac-1 and rac-8, because they display comparable
levels of toxicities and the structural difference between rac-1 and rac-8 is much larger when
compared to rac-1 and rac-4. At 100 µM, cell viability clearly decreased over a time period of
3 days when HUVEC were cultured in the presence of either rac-1 or rac-8 (Fig. 3.10). Since
at 50 µM cell viability remained above 95% throughout the culture period, in all long-term
cultures for VCAM-1 analysis ET-CORM concentrations were 50 µM or lower. While inhibition
of VCAM-1 expression by rac-1 slightly waned in time, VCAM-1 inhibition by rac-8 seems to
increase (Fig. 3.11). Inhibition of VCAM-1 expression was also observed for 2-cyclohexenone
(L1), but not for 1,3-cyclohexanedione (L2). To further substantiate that in long-term cultures
the inhibitory effect on VCAM-1 expression is much larger for rac-8 as compared to rac-1,
HUVEC were cultured for 5 days in the presence of 25 or 12.5 µM of either rac-1 or rac-8
(Fig. 3.12, top panel). Cell toxicity was not observed under these concentrations (Fig. 3.12,
bottom panel). VCAM-1 expression was inhibited by both compounds in a dose-dependent
manner, yet, rac-8 was clearly more effective as at both concentrations the inhibitory effect was
more pronounced for rac-8.
The propensity of rac-1 and rac-8 to down-regulate VCAM-1 expression was also present
when HUVEC were stimulated with TNF-α one day prior to the addition of these ET-CORMs
(Fig. 3.13). However, down-regulation of VCAM-1 expression required the continuous presence
of ET-CORM, as VCAM-1 reappeared upon removal of the ET-CORM (Fig. 3.14). In keeping
with the notion that for inhibition of VCAM-1 CO needs to be continuously present, current data
thus indicate that the difference in kinetic of VCAM-1 inhibition between rac-1 and rac-8 may
reflect differences in the amount of intracellular CO.
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Figure 3.9: Inhibition of VCAM-1 by rac-4 at low concentrations: To demonstrate that rac-4 also inhibits VCAM-1
expression at low, non-toxic concentrations, HUVEC were stimulated with TNF-α for 24 hours in the presence
or absence of different concentrations of rac-4. Note that at these concentrations inhibition of VCAM-1 occurs.
VCAM-1 expression was assessed by Western blotting, β-actin was used as loading control.
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Figure 3.10: Cell viability during long-term treatment with rac-1 and rac-8: HUVEC were grown in 96-well plates
until confluence and subsequently incubated with serial dilutions (0-400 µM) of rac-1 (top graph) or rac-8 (bottom
graph). Cell viability was assessed at different time points (24h, 48h and 72h) by MTT assay as described. All
experimental conditions were tested in triplicates in at least 5 independent experiments.
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Figure 3.11: Inhibition of VCAM-1 during long-term treatment with ET-CORMs: Cells were stimulated with
TNF-α for the indicated time periods in the presence or absence of 50 µM of rac-1, L1 (top graphs), rac-8 or L2
(bottom graphs). Compound L3 (Fig. 2.2) as an additional possible hydrolysis/disintegration product of rac-8 was
tested in various experiments and gave similar results as L2 (data not shown). Cells that were not stimulated with
TNF-α served as control. VCAM-1 expression was assessed by Western blotting; β-actin was used as loading
control. Data of a representative experiment are shown. At least 4 independent experiments have been performed.
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Figure 3.12: Inhibition of VCAM-1 and cytotoxicity after treatment with rac-1 and rac-8 for 5 days: Cells were
stimulated with TNF-α for 5 days in the presence or absence of 25 or 12.5 µM of rac-1 or rac-8. Cells that were
not stimulated with TNF-α served as control. VCAM-1 expression was assessed by Western blotting, β-actin
was used as loading control (top panel). HUVEC were grown in 96-well plates until confluence and subsequently
incubated with 12.5 or 25 µM of rac-1 or rac-8. Cell viability was assessed by MTT assay (bottom panel) and was
expressed as % viable cells relative to the untreated cells. Data of a representative experiment are shown. All
experimental conditions were tested in triplicates in at least 5 independent experiments.
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Figure 3.13: Inhibition of VCAM-1 after TNF-α pre-stimulation and treatment with rac-1 and rac-8: HUVEC
were stimulated for 24 hours with TNF-α (10 ng/ml). Hereafter, 50 µM of rac-1 or rac-8 was added without
changing the medium and the cells were cultured for additional 24 hours. VCAM-1 expression was assessed at 24
hours of TNF-α stimulation to assure that it was present before addition of rac-1 or rac-8 and after 48h to test if
addition of rac-1 or rac-8 was still able to affect VCAM-1 expression. Cells that did not receive rac-1/rac-8 served
as control. Cells that were not stimulated with TNF-α were included to demonstrate VCAM-1 induction. Data of
a representative experiment are shown. At least 4 independent experiments have been performed with essentially
the same result.
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Figure 3.14: Reversible inhibition of VCAM-1 after removal of rac-1 and rac-8: In separate experiments cells were
stimulated for 24 hours with TNF-α (10 ng/ml) in the presence or absence of 50 µM of rac-1 or rac-8. After 24
hours in separate wells, the medium was exchanged for medium that only contained TNF-α (10 ng/ml) (removal)
or medium that contained both TNF-α and rac-1 or rac-8 (presence) and cells were allowed to grow for additional
24 hours. VCAM-1 expression was assessed at 24 hours to demonstrate that rac-1 inhibits VCAM-1 expression
and after 48h to demonstrate that VCAM-1 expression reappeared after removal of rac-1 and rac-8 as well. Cell
cultures grown for 48h in the continuous presence of TNF-α (c) and cells that were not stimulated with TNF-α
were also included. Data of a representative experiment are shown. At least 4 independent experiments have been
performed with essentially the same result.
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3.2.3 Inhibition of NFκB and activation of Nrf2
In line with inhibition of TNF-α mediated VCAM-1 expression it was found that both rac-1
and rac-8 inhibit NFκB activation as demonstrated by reporter assay. Also 2-cyclohexenone
(L1), but not 1,3-cyclohexanedione (L2), was able to inhibit NFκB (Fig. 3.15). Inhibition of
NFκB was not caused by impaired IκBα degradation, in fact, the reappearance of IκBα in the
cytoplasm was consistently found to be slightly retarded for both ET-CORMs (Fig. 3.16). Apart
from inhibition of NFκB, a significant activation of Nrf2 for both ET-CORMs was also observed
(Fig. 3.17, top panel), which was paralleled by the induction of HO-1 at the mRNA- and protein
level (Figs. 3.17, bottom panel, and 3.18). Similar as observed for NFκB, only the hydrolysis
product of rac-1 but not of rac-8, affected Nrf2 activation and consequently HO-1 expression.
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Figure 3.15: Inhibition of NFκB by ET-CORMs: HUVEC were transduced by a lentiviral particle with an inducible
promoter construct containing dual NFκB-consensus motifs and with a constitutively active CMV-driven promoter
construct both cloned behind luciferase cDNA. Two days after transduction the cells were stimulated for 24 hours
with TNF-α (10 ng/ml) in the presence or absence of 50 µM rac-1, rac-8, L1 (2-cyclohexenone) or L2 (1,3-
cyclohexanedione), respectively. Hereafter luciferase expression was measured as described in the methods section.
Inducible luciferase expression was normalized for constitutively expressed luciferase to control for differences in
transduction efficiency. The data of 4 independent experiments are expressed as mean fold increase ± SD relative
to TNF-α stimulated cells. n.s.: not significant, ∗∗ P< 0.01 vs. TNF-α stimulated cells.
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Figure 3.16: IκBα degradation: HUVECs were treated for 4h with 50 µM rac-1 or rac-8 before stimulation with
TNF-α. ET-CORMs were present during stimulation. Cell lysates were directly prepared after 15, 30, 45 and 60
minutes of TNF-α stimulation and subjected to electrophoresis and Western blotting for analysis of IκBα expression
and β-actin as loading control. Cells that were not stimulated with TNF-α were included to assess constitutive
levels of IκBα. The data of a representative experiment is depicted. At least 4 independent experiments have been
performed with essentially the same results.
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Figure 3.17: Activation of Nrf2 and induction of HO-1 (hmox1) expression by ET-CORMs: Top: HUVEC were
transduced by a lentiviral particle with an inducible promoter construct containing dual ARE motifs and with
a constitutively active CMV-driven promoter construct both cloned behind luciferase cDNA. Two days after
transduction the cells were treated for 24 hours with 50 µM rac-1, rac-8, L1 (2-cyclohexenone) or L2 (1,3-
cyclohexanedione) respectively. Hereafter, luciferase expression was measured as described in the methods section.
Inducible luciferase expression was normalized for constitutively expressed luciferase to control for differences in
transduction efficiency. The data of 4 independent experiments are expressed as mean fold increase ± SD relative
to untreated cells (medium). n.s.: not significant, ∗∗ P < 0.01, vs. untreated cells (medium). Bottom: HUVEC
were treated for 24 hours with 50 µM rac-1 or rac-8 or left untreated. Hereafter, total RNA was isolated and the
expression of HO-1 (hmox1) was quantitated by qPCR and normalized for equal GAPDH expression. Normalized
hmox1 mRNA levels are expressed as mean fold increase ± SD relative to untreated cells (medium), ∗∗ P < 0.01,
vs. untreated control.
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Figure 3.18: Induction of HO-1 expression by ET-CORMs: HUVEC were treated for 24 hours with the indicated
concentrations of rac-1, L1, rac-8 or L2. Hereafter, protein extracts were made and HO-1 expression was assessed
by Western blotting, β-actin was used as loading control. The data of a representative experiment are depicted.
At least 4 independent experiments have been performed with essentially the same results.
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Discussion
Advancing insights in the biological properties of carbon monoxide have clearly changed our way of
looking at this class of gasotransmitter: Initially being considered a poisonous gas, recent findings
suggest the utilization as a signaling molecule with potential therapeutic effects. Although
being the simplest way of application, CO inhalation also threw-up hurdles as it significantly
affects the oxygen-carrying capacity of blood. This has pushed CO therapeutic research towards
other application modalities and paved the way to design drug molecules that release carbon
monoxide in a controllable manner [Motterlini et al., 2005a; Romao et al., 2012; Zobi, 2013].
The mostly utilized CO-releasing molecule, i.e., CORM-3, clearly revealed the therapeutic efficacy
in pre-clinical studies. These promising findings lead to the synthesis of enzyme-triggered CORMs
that enable for direct intracellular CO release and promise a more specific CO delivery [Romanski
et al., 2011a,b].
This dissertation focused on the biological properties of selected ET-CORMs. This study in
essence aimed to differentiate if cytotoxicity is mediated by the release of CO and subsequent
inhibition of cell respiration or by the concomitant release of iron. The comportment of the
biological activity during long-term treatment in terms of reducing pro-inflammatory adhesion
molecules was assessed and the involvement of transcription factors in the regulation of VCAM-1
expression was evaluated [Stamellou, Storz et al., 2014]. The relevance of structural alterations
for biological efficacy was also studied by using enantiomers of one ET-CORM, the results of
which will be discussed first.
4.1 Relevance of structural alterations and biological
efficacy of ET-CORM enantiomers
Previous studies on ET-CORMs already showed that structural differences translate into significant
changes in biological activity. Accountable for this are differences in the mother compound from
which the ET-CORMs are derived, and the type and position of the ester functionality they harbor
[Romanski, 2013]. Since this has not been demonstrated for enantiomers, the present study
assessed if enantiomers of ET-CORMs (like those that differ structurally) also display differences
in their efficacy to mediate a biological response, i.e., cytotoxicity, inhibition of inflammation
and protection against cold inflicted cell damage. ET-CORM enantiomers possess the same
mother compound and carry the same ester functionality at the same position but differ in the
orientation of their functional groups being either in a trans or cis orientation.
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The current data set on cytotoxicity, anti-inflammation (VCAM-1 and HO-1 expression) and cold
preservation injury reveals a consistent difference that the biological activity of cis-enantiomers
was more pronounced when compared to the trans-enantiomers. In terms of cytotoxicity and
anti-inflammatory effects, cis-enantiomers demonstrate efficiency at lower concentrations (25
µM) when compared to trans-enantiomers at higher concentrations (50 µM) (Figs. 3.1 and 3.2).
This indicates that lower concentrations of cis-enantiomers have similar cytotoxic effects and
similar, if not stronger, anti-inflammatory properties when compared to trans-enantiomers at
higher concentrations. Furthermore, with respect to protection against cold inflicted cell damage,
the cis-enantiomers were more effective (Fig. 3.3). Within the cis-enantiomers, Stro 790-C
showed a tendency to be more effective in terms of cytotoxicity and anti-inflammation, while no
difference was found in this respect for prevention of cold inflicted injury.
Although these results provide relevant structural information for designing of new ET-CORMs,
the underlying reason for the differences between the cis and trans orientation remains unclear.
Differences in cellular uptake and differences in decomposition of the compounds might both
play a role.
4.2 Biological activity of ET-CORMs
4.2.1 Intracellular carbon monoxide
After intracellular uptake of ET-CORMs, release of carbon monoxide from the ET-CORMs occurs
in two steps. First, esterase-dependent hydrolysis of the ester moiety and, second, oxidative
disintegration of the remaining labile enol complex, leading to liberation of carbon monoxide,
ferric iron and the corresponding mother compound (Fig. 1.2) [Romanski et al., 2012, 2011a].
Regarding the enzymatic cleavage of ET-CORMs, this study demonstrates that the position of
the ester moiety appears to be of crucial importance for CO release and therefore for the efficacy
to mediate a particular biological response. The 2-cyclohexenone (L1) derived molecules, i.e.,
rac-1 and rac-4, unveil a substantial difference in cytotoxicity (Fig. 3.6). Since both compounds
have an acetate as ester functionality, a comparison to other 2-cyclohexenone derived ET-CORMs
(Fig. 1.1) [Romanski et al., 2013] suggests that their CO releasing characteristics not only emerge
from differences in hydrolysis efficiency but may well include the ease of oxidative disintegration.
Indeed, the data on CO release by rac-1 and rac-4 (Fig. 3.5) are in line with previous reports that
CO release occurs much easier for rac-4 than for rac-1 [Romanski, 2013; Romanski et al., 2012,
2013]. In conclusion, the large difference in cytotoxicity between the 2-cyclohexenone derived
ET-CORMs might be explained by the fact that esterase-triggered oxidative disintegration of
the rac-4 compound occurs at higher rate when compared to rac-1.
This study also suggests that the disparity in mediating a biological response is unlikely mediated
by differences in cellular uptake of rac-1 and rac-4. Cyclodextrin formulations, e.g., RAMEB,
are frequently used as drug delivery platform for hydrophobic compounds. These bind to
the hydrophobic inner-core of the cyclodextrin molecule while the outside of the molecule is
hydrophilic, thereby making the complex water soluble. The uptake of the complex now no longer
depends on the chemophysical properties of the drug but rather depends on the cyclodextrin
carrier. Accordingly, it is expected that for the RAMEB complexes, i.e., RAMEB@rac-1 and
RAMEB@rac-4, it is not the ET-CORMs itself, but the chemical properties of the cyclodextrin
formulation that mainly determines the cellular uptake. Yet, the difference in the cytotoxic profile
between the two compounds persisted (Fig. 3.6).
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Regarding rac-8, the compound derived from 1,3-cyclohexanedione (L2) harbouring two pivalate
ester moieties demonstrates a significantly higher cytotoxicity when compared to the mono-
acetate and L1 derived rac-1 [Romanski et al., 2012, 2013]. Previously published data on
ester-containing prodrugs suggest pivalate esters to be sterically demanding functionalities in
terms of esterase dependent hydrolysis [Shoman et al., 2011; Takahashi et al., 1995]; hydrolysis
of rac-8 is therefore expected to be comparably slow. The esterase-dependent hydrolysis of this
compound is therefore expected to be comparably slow. Consequentially, this might explain why
the levels of toxicity between rac-1 and rac-8 were comparable (Fig. 3.10) despite the fact that
rac-8 contains one ester functionality at the outer-position, which, as shown for rac-4, is in
general associated with a faster CO release.
At high and thus toxic concentrations, carbon monoxide is expected to target and bind to
intracellular haem-containing proteins [Schatzschneider, 2015], leading to impairment of cell
respiration [Sandouka et al., 2005], presumably via inhibition of the mitochondrial cytochrome c
oxidase (COX) [Zuckerbraun et al., 2007]. The modulating mechanism of CO on cellular response
to stress is only partially understood. However, the data indicating that a decrease in ATP
production promotes cell damage further supports the hypothesis that there might be a causal
connection between cytotoxicity of ET-CORMs and cellular respiration (Fig. 3.8). Interestingly,
the present study demonstrates a significant increase of ATP levels when the cells are treated with
ET-CORMs at low concentrations (Fig. 3.8, top graph). This is in concordance with previous
studies suggesting that low concentrations of CO application, either gaseous or as CORM-3,
lead to increased ATP production. These studies are giving indications that the increase in
ATP levels might be mediated by activation of soluble guanyl cyclase (sGC) [Derbyshire and
Marletta, 2012; Tsui et al., 2007, 2005] and additionally, that this involves increased enzymatic
activity of cytochrome c oxidase (COX, complex IV of the respiratory chain) as well as increased
mitochondrial oxygen consumption (state II respiration) indicating an enhancement of oxidative
phosphorylation [Almeida et al., 2012; Lo Iacono et al., 2011; Sandouka et al., 2005].
Several studies clearly demonstrate the inhibitory effects of carbon monoxide on the expression of
adhesion molecules and its anti-inflammatory modulation in vitro and in vivo [Caumartin et al.,
2011; Katada et al., 2010; Qin et al., 2013; Song et al., 2009]. Carbon monoxide is assumed to
induce HO-1, which subsequently may impede the expression of inflammatory mediators [Lee
et al., 2006; Seldon et al., 2007]. Consequently, ET-CORMs are able to inhibit VCAM-1 and to
induce HO-1 expression, as data of the previous study confirm [Romanski et al., 2013].
In cellular responsiveness to pro-inflammatory stimuli NFκB plays a key role as a rapid acting
transcription factor. In the classical (canonical) pathway, NFκB dimers are bound to IκBα in
unstimulated cells, which keeps the dimers sequestered and inactive. An inflammatory stimulus,
e.g., TNF-α or LPS, induces the degradation of IκBα via signal-induced activation of the IκB
kinase (IKK) leading to phosphorylation and subsequent dissociation of IκBα. Furthermore, the
phosphorylated IκBα is ubiquitinated and degraded in the proteasome. The released NFκB enters
the nucleus, binds to specific DNA-binding sites and induces the transcription of proinflammatory
cytokines, chemokines and adhesion molecules, such as VCAM-1 [Gilmore, 2006; Hayden et al.,
2006] (Fig. 4.1, left side). The present study demonstrates that ET-CORMs may mediate
inhibition of TNF-α-induced VCAM-1 expression via inhibition of NFκB, presumably in an IκBα
independent manner (Figs. 3.15 and 3.16).
Another important transcription factor is Nrf2 that controls the expression of antioxidant proteins.
Under homeostatic conditions, Nrf2 is bound to Keap1, an adaptor component of a Cul3 (cullin
3)-based ubiquitin E3 ligase complex, which promotes ubiquitination and proteasomal degradation
of Nrf2. Oxidative stress, i.e., reactive oxygen species (ROS) and/or GSH depletion, lead to
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Figure 4.1: Pathways of NFκB and Nrf2: Pathways of NFκB (classical pathway; left side) and Nrf2 (right side;
own illustration).
dissociation of the Keap1-Cullin 3 complex, thereby preventing Nrf2 to become ubiquitinated and
degraded. In fact, the dissociated Nrf2 now has the propensity to translocate into the nucleus
where it binds to the antioxidant response element (ARE) in the promoters of genes encoding
anti-oxidative proteins such as HO-1 [Ishii et al., 2000; Ryter and Choi, 2009] (Fig. 4.1, right
side). The current data indicates that ET-CORMs can additionally activate Nrf2 (Fig. 3.17).
This is in concordance with previously published studies assuming that CO might activate the
Nrf2 signaling pathway [Chi et al., 2015; Kim et al., 2011].
Interestingly, there is evidence that ET-CORMs are able to diminish already existing VCAM-1
expression and that the inhibition of VCAM-1 is reversible, once ET-CORMs are removed
(Figs. 3.13 and 3.14).
Regarding potential anti-inflammatory effects of the 2-cyclohexenone (L1) derived rac-1 and
rac-8, derived from 1,3-cyclohexanedione (L2), it could be observed that L1 but not L2 inhibits
VCAM-1 and induces HO-1, the same applies to inhibition of NFκB and activation of Nrf2. In
addition, rac-8 seems to inhibit VCAM-1 slower and in a longer lasting manner when compared
to rac-1. This is in concordance with the previous hypothesis that rac-8 represents a higher
resistance to hydrolysis suggesting a slower CO release. An alternative explanation in this case
might be the fact that L1 contributes to VCAM-1 inhibition, whereas L2 and L3 do not.
46
Chapter 4 Discussion
4.2.2 Free intracellular iron
Efficient iron homeostasis, both intracellular and systemic, involves ambitious tasks such as
coordination of iron uptake, utilization, and storage to assure adequate supply and to prevent
cytotoxicity [Hentze et al., 2010]. Intracellular, the basal level of easy mobilized and redox-active
iron is defined as labile cell iron (LCI) or labile iron pool (LIP) [Greenberg and Wintrobe, 1946;
Jacobs, 1976]. LCI comprises both Fe2+ and Fe3+ [Kakhlon and Cabantchik, 2002] and is
considered as a transitory and dynamic parameter, which varies with the cellular pH, the redox
potential of the medium and the repertoire of substances with chelating moieties [Cabantchik,
2014]. Iron regulatory proteins (IRP) play an important role in controlling intracellular iron
homeostasis. In iron-deficient cells IRP inhibit translation of ferritin among other things, whereas
high intracellular iron levels promote IRP ubiquitination and degradation, leading to transcription
of ferritin [Cairo and Recalcati, 2007; Muckenthaler et al., 2008]. Ferritin itself binds and oxidates
ferrous iron (Fe2+) into chemically less reactive ferric iron (Fe3+) [Jacobs et al., 1989], stores
the latter and thus limits the generation of toxic radicals.
An excessive rise in LCI however, will lead to compromised cell integrity, mitochondrial iron
accumulation and most importantly to catalytic transformation of reactive oxygen intermediates
(ROI) to noxious reactive oxygen species (ROS) [Kakhlon and Cabantchik, 2002; Kruszewski,
2003]. Products of this Fenton reaction, such as hydroxyl radicals, lead to oxidative stress
[Kruszewski, 2004]. Once the intracellular antioxidant buffer is depleted, the imbalance will lead
to cell damage [Kruszewski, 2003; Muckenthaler et al., 2008]. Interestingly, oxidative stress
induces haem oxygenase-1 (HO-1) [Applegate et al., 1991], which itself further induces ferritin
[Balla et al., 1992; Gonzales et al., 2002] and inhibits apoptosis by regulating cellular prooxidant
iron [Brouard et al., 2000; Otterbein and Choi, 2000].
In contrast to liberated ferrous iron (Fe2+) during degradation of haem or cellular distribution of
iron through transferrin, ET-CORMs distribute ferric iron, i.e., Fe3+, the chemically less reactive
form. Since iron homeostasis needs to be strictly maintained the fate of the concomitantly
released Fe3+ needs to be addressed, as this may also jeopardize iron homeostasis. It is unlikely
that the released Fe3+ contributes to cell toxicity of ET-CORMs as toxicity for FeCl2 or FeCl3 was
observed at much higher concentration as compared to rac-4 (Fig. 3.7, top graph). Additionally,
iron chelators abrogated FeCl2/FeCl3-mediated toxicity, whereas this was not observed for rac-4
(Fig. 3.7, bottom graph). It is assumed that the released ferric iron may lead to induction of
ferritin, thus preparing the cells to scavenge potential redox substrates, e.g., Fe2+.
4.2.3 The role of the mother compound
As demonstrated in this study, 2-cyclohexenone (L1), the mother compound of rac-1 and rac-4,
liberated during ET-CORM cleavage contributes to the bioactivity of the latter. L1 activates
Nrf2 (Fig. 3.17), and inhibits VCAM-1 expression (Fig. 3.11, top graphs) most likely via inhibition
of NFκB. In contrast to rac-1 and rac-4, L1 was neither cytotoxic nor was it able to protect
cells against cold preservation injury [Romanski et al., 2013]. The current data suggests that
released CO and the hydrolysis product L1 may act in a synergistic or complementary manner.
Hence, ET-CORMs might be considered as bifunctional, i.e., they can release two functional
mediators. For the other gasotransmitter, i.e., NO and H2S, bifunctional gasotransmitter-based
complexes have already been reported: The so-called cyclooxygenase inhibiting nitric oxide donors
(CINODs) and H2S-releasing NSAIDs [Fiorucci and Distrutti, 2011]. NO-naproxen (Naproxcinod),
for instance, is a nitrosylated naproxen derivative with the ability to release nitric oxide (NO)
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[Cicala et al., 2000], which was already investigated in clinical trials [White et al., 2011]. As for
hydrogen sulfide, there are complexes available that contain H2S-releasing groups on naproxen
and diclofenac respectively, i.e., ATB-346 and ATB-337, which are investigated in vivo [Campolo
et al., 2013; Dief et al., 2015; Herrera et al., 2015; Wallace et al., 2010, 2007]. With respect to
rac-8, the mother compound, i.e., 1,3-cyclohexanedione (L2) or the enol pivalate (L3) (Fig. 2.2)
show neither effects on cytotoxicity [Romanski, 2013], VCAM-1 inhibition (Fig. 3.11, bottom
graphs and Fig. 3.15) and HO-1 induction (Figs. 3.17 and 3.18), nor protection against cold
preservation injury (data not shown). Hence it is most likely, that the bioactivity of rac-8 evokes
primarily by the release of CO.
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Limitations and Future Prospects
Enzyme-triggered CO-releasing molecules pursue the seminal feasibility of tissue-targeted CO
delivery. It has to be admitted that intracellular esterases are ubiquitous therefore CO delivery
with true tissue-specificity is not guaranteed with the current ET-CORMs. Thus, currently
available ET-CORMs need to be structurally optimized to be cleaved by either esterase subforms
or tissue-specific enzymes to aim for cell restricted CO release.
In fact, so-called protease-triggered CORMs have been developed and implemented in in vitro
experiments [Sitnikov et al., 2015]. These compounds are designed as oxydiene-Fe(CO)3
complexes with a peptide sequence as a side chain that is cleaved by penicillin G amidase (PGA).
PGA-induced release of CO showed inhibition of VCAM-1 expression and induction of HO-1
in HUVEC [Sitnikov et al., 2015]. Admittedly, further exploration is necessary, although this
promising data serves as a fundament to design ET-CORMs cleaved by tissue-specific proteases.
Furthermore, ET-CORMs may be linked to a vector for cell-specific intracellular uptake. Similarly
to the cyclodextrin formulation, this vector would act as a smart coat pharmaceutical or a
specific carrier conjugate that could transfer the compound to a particular tissue. A potential
vector might be bile acid, which can only be absorbed by specific cells, i.e., hepatocytes or
enterocytes, showing particular bile acid transporters. Zobi et al. addressed to the problem
of cellular internalization with conjugation of photoCORM to vitamin B12. Cyanocobalamin
(B12) is used as a water-soluble vector to transport photoCORM into nonspecific cells, following
photolysis [Zobi et al., 2013]. Similarly, Mede et al. modified manganese(I)-based photoCORMs
that are enzymatically transformed inside of cells to trap the complexes and to ensure intracellular
photo-triggered release of carbon monoxide [Mede et al., 2018].
The principle of conjugating CORMs to a vector is currently investigated within several studies.
CORMs have been synthesized with various carriers such as proteins, nanoparticles and micelles
to ameliorate stability and kinetics [Garcia-Gallego and Bernardes, 2014; Inaba et al., 2015;
Kautz et al., 2016].
In the last years fluorescent sensors were introduced to detect CO release in living cells. A CO
sensor (COSer) is a genetically encoded fluorescent probe with the need to be transfected into
cells [Wang et al., 2012], whereas CO-Probe 1 (COP-1) is a chemical reagent that interacts
with carbon monoxide to trigger a fluorescent reaction [Michel et al., 2012]. In this study COP-1
was used to evaluate the speed and extent of intracellular CO release. As demonstrated, it
was possible to evaluate CO liberation. However, difficulties evolved from a high background
fluorescence signal of COP-1.
Promising new fluorescent CO detectors have been presented most recently holding the advantage
of detecting even endogenous CO generation over the well-known COSer and COP-1 [Feng
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et al., 2016; Li et al., 2016]. Further research and technical advances of the probes are necessary
to visualize intracellular levels of carbon monoxide in order to assess its biological activities and
signaling effects.
To this day, it has been complicated to specify chemical components of LCI [Cabantchik, 2014]
and to describe the role of changes in iron metabolism during inflammation and interactions
between inflamed tissue and cells of the immune system [Hentze et al., 2010]. Within this study,
ET-CORMs were additionally evaluated using a Phen Green Assay (Thermo Fisher Scientific).
The assembled data showed no reproducibility, and neither dynamic tracing nor evaluation of the
potency of ferric iron release were possible (data not shown). There is not only a necessity to
determine the dynamic parameter LCI in living cells but also to observe the intracellular (and
systemic) iron homeostasis with the help of novel metallosensors.
This study demonstrates that, first, ET-CORMs inhibit VCAM-1 expression, potentially reducing
leukocyte adhesion and diapedesis, and, second, presumably induce HO-1 in an independent
manner. This is in concordance with previous studies showing inhibition of production of
inflammatory cytokines in LPS-stimulated macrophages [Otterbein et al., 2000; Sawle et al.,
2005] and possibly modulation of initiation of immune responses [Otterbein et al., 2003a]
after administration of CO. Alternative studies demonstrate a reduction of infiltration of T
cells, leukocytes and macrophages in transplant recipients of aortic grafts after CO inhalation
[Otterbein et al., 2003b]. Focused on the acquired immune system, upregulation of HO-1 and
therefore endogenous production of CO was proposed to influence the function of CD4+CD25+
regulatory T cells in immunosuppression [Brusko et al., 2005].
To evaluate if ET-CORMs show modulatory effects on the acquired immune system, naive
CD4+ T cells isolated from PBMC were used to conduct the MTT cell toxicity assay and
3H-thymidine incorporation assay. While MTT cell toxicity assay showed similar results in terms
of cytotoxicity when compared to experiments with HUVEC, 3H-thymidine incorporation assay
with different ET-CORMs using concentrations of 25 µM to 100 µM showed no clear effect on
proliferation of naive CD4+ T cells, neither definite inhibition nor stimulation when compared
to positive or negative control (data not shown). The inconclusive results and the lack of data
on the effects of CO or CORMs especially on CD4+ T cells need continuative attention since
modulation of the adaptive immune system could be another interesting quality of ET-CORMs
in terms of reduction of graft versus host reactions and graft rejection in transplant recipients.
Despite the beneficial effects of L1, little is known about the intracellular interactions, the
systemic metabolism and the biological relevance of the mother compounds, i.e., L1 as well as
L2 and L3. As soon as ET-CORMs are further evaluated in vivo, this might lead to profound
knowledge of this issue. Simultaneously, our findings imply the intriguing opportunity to further
design and optimize ET-CORMs as bifunctional complexes.
As demonstrated in this study, this is partially already in existence. The 2-cyclohexenone (L1)
derived ET-CORMs, i.e., rac-1 and rac-4 can act as bifunctional complexes in a way that the
by-products summate the beneficial outcome in terms of VCAM-1 inhibition and induction
of HO-1. The design of bifunctional gasotransmitter-based molecules has been reported for
NO and H2S, as described before. The principle behind bifunctional compounds regarding
synergistic and complementary products is very interesting and intriguing. Several in vivo studies
imply a protective effect of CO in inflammatory bowel disease [Takagi et al., 2015], mostly
by regulation of intestinal inflammation [Babu et al., 2015b]. Combining ET-CORMs with
conventional pharmaceuticals to design bifunctional carbon monoxide-based complexes, e.g., for
topical application in inflammatory bowel disease or inflammatory diseases of the skin, would be
an ambitious approach opening numerous opportunities.
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In fact, it has already been demonstrated that this approach is feasible by introducing novel methyl
fumarate-derived compounds (FumET-CORMs). Dimethyl fumarate is used as a treatment
in psoriasis and multiple sclerosis and is known as a strong anti-inflammatory agent. Hence,
Bauer et al. combined the anti-inflammatory effects of dimethyl fumarate and ET-CORMs to
synthesize the bifunctional FumET-CORMs. It could be demonstrated that combined synergistic
anti-inflammatory effects of FumET-CORMs are more pronounced compared to each compound
on its own, especially compared to the clinically used dimethyl fumarate [Bauer et al., 2017].
Further promising approaches are Oral Carbon Monoxide Release Systems (OCORS). Steiger et
al. introduced a localized and controlled oral drug delivery of carbon monoxide in vitro and in vivo.
Therefore, ruthenium-containing CORM-2 was formulated to micro scale OCORS (M-OCORS)
demonstrating preventive effects in chemically induced colitis in mice. In addition, the scientists
introduced the principle of enzyme-triggered Oral Carbon Monoxide Release Systems (E-OCORS)
formulating ET-CORM/RAMEB complexes for oral administration [Steiger et al., 2016].
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Conclusion
In this work a comprehensive investigation of selected ET-CORMs with respect to their biological
activity was conducted [Stamellou, Storz et al., 2014]. The chemical design of ET-CORMs holds
particular advantages over present forms of CO application. CO inhalation and other CORMs
predominantly deliver CO via unspecific passive diffusion to cells or tissue, whereas ET-CORM
release CO only intracellularly in an esterase dependent manner. When compared to existing
CORMs, e.g., frequently used CORM-3, lower concentrations of ET-CORMs can be applied to
cells to achieve similar biological activities. Although a direct comparison between ET-CORMs
and CORM-3 was not yet performed, this study demonstrates complete inhibition of VCAM-1
expression at 50 µM of rac-1 (Fig. 3.11) and at 3 µM of rac-4 (Fig. 3.9). On the contrary, for
CORM-3, 1 mM has been required to completely inhibit TNF-α mediated VCAM-1 expression
[Song et al., 2009]. This study revealed clear indication that the cytotoxic effect of ET-CORMs
particularly depends on the release of CO, i.e., the speed or extent of CO release, for the following
reasons. Firstly, the disparity in cytotoxicity is unlikely due to differences in cellular uptake as
cyclodextrin formulated ET-CORMs indicate (Fig. 3.6). Secondly, the mother compounds itself,
i.e., L1, L2 and L3 show no cytotoxic effect [Romanski et al., 2013]. Thirdly, there is no
indication that released ferric iron contributes noticeably to the cytotoxic effect, since cytotoxicity
was observed at a much higher concentration using FeCl2 and FeCl3 (Fig. 3.7, top graph).
Additionally, iron chelators were able to abrogate toxic effects of FeCl2 and FeCl3, whereas
cytotoxicity of rac-4 persisted (Fig. 3.7, bottom graph). Fourthly, the data further supports the
hypothesis that there might be a causal connection between impairment of cellular respiration
and cytotoxicity of ET-CORMs via release of CO (Fig. 3.8). This thesis also demonstrated
that ET-CORMs effectively inhibit the expression of VCAM-1 upon TNF-α stimulation. During
long-term treatment, rac-8 appears to inhibit VCAM-1 in a slower and longer lasting manner
when compared to rac-1. ET-CORMs may mediate the inhibition of NFκB, presumably in an
IκBα independent manner, and activate the antioxidant Nrf2 pathway, leading to induction of
HO-1. Regarding the mother compounds 2-cyclohexenone (L1) and 1,3-cyclohexanedione (L2),
it could be observed that L1 but not L2 inhibits VCAM-1 and induces HO-1, the same applies
to inhibition of NFκB and activation of Nrf2. In this matter, there might be a summation of
beneficial properties in 2-cyclohexenone derived ET-CORMs. Finally, the findings on ET-CORM
enantiomers may furthermore help designing favorable ET-CORMs with improved bioactivity. In
addition to the different possibilities in structural optimization of ET-CORMs, the current work
warrants in vivo studies. Ultimately, this may lead to the development of novel pharmaceuticals
that deliver carbon monoxide in a highly tissue-specific manner to overcome side effects and to
focus the therapeutic effects to organs where they are most needed.
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Summary
Carbon monoxide (CO) is an ambivalent gasotransmitter endogenously generated during physio-
logical degradation of haem. While being highly toxic at elevated concentrations, the gaseous
molecule holds promising properties at low and physiological concentrations. Application of the
exogenous equivalent can mimic these beneficial characteristics including cytoprotective and
anti-proliferative effects as well as anti-inflammatory properties.
Enzyme-triggered CO-releasing molecules (ET-CORMs) are a novel class of transition metal
carbonyl complexes that offer several advantages over previous forms of exogenous CO application.
While inhalation of CO and other CORMs predominantly deliver carbon monoxide via unspecific
passive diffusion to cells or tissue, ET-CORMs allow for an intracellular administration of carbon
monoxide. More precisely, esterase dependent, enzymatic cleavage of the chemical bonds leads
to intracellular release of carbon monoxide, ferric iron and the mother compound. Previously
published data demonstrates that the biological properties of ET-CORMs strongly depend on
their chemical structure, the type and position of the ester substituent as well as the mother
compound from which they are derived.
In this work a series of structurally different ET-CORMs (rac-1, rac-4 and rac-8) were investigated
in human umbilical vein endothelial cells: The data showed that the cytotoxic effect of ET-CORMs
relies on the speed or extent of carbon monoxide release. The disparity in cytotoxicity is unlikely
to be mediated by different intracellular uptake of the investigated compounds based on the
notion that the cellular uptake of the purpose-built cyclodextrin encapsulated ET-CORMs is equal
and the cytotoxic profile remained unaltered. At toxic concentrations, there was no indication
that released ferric iron or the mother compounds contribute noticeably to the cytotoxic effect
of ET-CORMs. In this case (i.e., toxic concentrations of CO), it is expected that CO binds to
intracellular haem containing proteins leading to an impairment of cell respiration. The collected
data demonstrates that ATP depletion promotes cell damage, thus supporting the hypothesis of
a causal connection between the cytotoxicity of ET-CORMs and cellular respiration. On the
contrary, treatment with ET-CORMs at low concentrations significantly increases intracellular
ATP levels. This is in agreement with previous studies on exogenous CO application suggesting
that the increase in ATP levels might be mediated by activation of soluble guanyl cyclase, which
in turn indicates an enhancement in oxidative phosphorylation.
In terms of anti-inflammatory modulation, the investigated ET-CORMs effectively inhibited
TNF-α induced VCAM-1 expression and may mediate the inhibition of VCAM-1 via inhibition of
NFκB, presumably in an IκBα independent manner. Additionally, ET-CORMs showed activation
of the Nrf2 signaling pathway leading to induction of the antioxidant protein HO-1. It is well
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known that both the NFκB and Nrf2 signaling pathway are crucial for the cellular response and
regulation to inflammatory stimuli.
The mother compound of rac-1 and rac-4 itself, i.e., 2-cyclohexenone (L1), inhibited VCAM-1
and induced HO-1 expression. Accordingly, L1-derived ET-CORMs can act as bifunctional
complexes in a way that the beneficial effects of the by-products summate. This opens up various
opportunities for the complementary delivery of ET-CORMs and a second agent.
Finally, enantiomers of ET-CORMs displayed differences in the efficacy to mediate a biological
response, providing essential structural information. Cis-enantiomers showed a pronounced
biological activity in terms of cytotoxicity, anti-inflammation and cold preservation injury when
compared to trans-enantiomers. This information can be employed to chemically modify and
thus optimize existing ET-CORMs.
Although intracellular esterases are ubiquitous and tissue-targeted delivery of CO based on
ET-CORMs cannot be guaranteed at this point, this work set a first foundation on the road
to tissue-specific delivery of carbon monoxide generating fundamental insights for designing
ET-CORMs with differential CO release and biological activities.
56
List of Figures
1.1 Exemplification of ET-CORMs . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2 Decomposition of ET-CORMs . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.1 ET-CORMs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2 Enones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3 Trans-enantiomers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.4 Cis-enantiomers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.1 Cytotoxicity of ET-CORM enantiomers . . . . . . . . . . . . . . . . . . . . . . 24
3.2 Inhibition of VCAM-1 and induction of HO-1 by ET-CORM enantiomers . . . . 25
3.3 LDH release during cold preservation by ET-CORM enantiomers . . . . . . . . 26
3.4 Tolerance to hypothermia due to treatment with ET-CORM enantiomers . . . . 27
3.5 Release of CO by cyclodextrin formulated ET-CORMs . . . . . . . . . . . . . . 29
3.6 Cytotoxicity for rac-1, rac-4 and cyclodextrin encapsulated ET-CORMs . . . . 30
3.7 Iron-mediated toxicity compared to rac-4 (with or without iron chelator) . . . . 31
3.8 Effects on intracellular ATP-levels by rac-1 and rac-4 . . . . . . . . . . . . . . 32
3.9 Inhibition of VCAM-1 by rac-4 at low concentrations . . . . . . . . . . . . . . . 34
3.10 Cell viability during long-term treatment with rac-1 and rac-8 . . . . . . . . . . 34
3.11 Inhibition of VCAM-1 during long-term treatment with ET-CORMs . . . . . . . 35
3.12 Inhibition of VCAM-1 and cytotoxicity after treatment with rac-1 and rac-8 for 5
days . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.13 Inhibition of VCAM-1 after TNF-α pre-stimulation and treatment with rac-1 and
rac-8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3.14 Reversible inhibition of VCAM-1 after removal of rac-1 and rac-8 . . . . . . . . 38
3.15 Inhibition of NFκB by ET-CORMs . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.16 IκBα degradation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.17 Activation of Nrf2 and induction of HO-1 (hmox1) expression by ET-CORMs . 41
3.18 Induction of HO-1 expression by ET-CORMs . . . . . . . . . . . . . . . . . . . 42
4.1 Pathways of NFκB and Nrf2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
57
List of Tables
2.1 Chemicals, mediums and reagents. . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.2 Prepared buffers and solutions. . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.3 Kits. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.4 Devices and equipment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.5 Composition of SDS-gel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.6 Antibodies for Western blotting. . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.7 First strand cDNA synthesis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
58
Bibliography
Alberto, R. and Motterlini, R. (2007). Chemistry and biological activities of co-releasing molecules
(corms) and transition metal complexes. Dalton Trans, (17):1651–60.
Almeida, A. S., Queiroga, C. S., Sousa, M. F., Alves, P. M., and Vieira, H. L. (2012). Carbon
monoxide modulates apoptosis by reinforcing oxidative metabolism in astrocytes: role of bcl-2.
J Biol Chem, 287(14):10761–70.
Applegate, L. A., Luscher, P., and Tyrrell, R. M. (1991). Induction of heme oxygenase: a general
response to oxidant stress in cultured mammalian cells. Cancer Res, 51(3):974–8.
Babu, D., Leclercq, G., Goossens, V., Remijsen, Q., Vandenabeele, P., Motterlini, R., and
Lefebvre, R. A. (2015a). Antioxidant potential of corm-a1 and resveratrol during tnf-
alpha/cycloheximide-induced oxidative stress and apoptosis in murine intestinal epithelial
mode-k cells. Toxicol Appl Pharmacol.
Babu, D., Motterlini, R., and Lefebvre, R. A. (2015b). Co and co-releasing molecules (co-rms)
in acute gastrointestinal inflammation. Br J Pharmacol, 172(6):1557–73.
Balla, G., Jacob, H. S., Balla, J., Rosenberg, M., Nath, K., Apple, F., Eaton, J. W., and
Vercellotti, G. M. (1992). Ferritin: a cytoprotective antioxidant strategem of endothelium. J
Biol Chem, 267(25):18148–53.
Bathoorn, E., Slebos, D. J., Postma, D. S., Koeter, G. H., van Oosterhout, A. J., van der Toorn,
M., Boezen, H. M., and Kerstjens, H. A. (2007). Anti-inflammatory effects of inhaled carbon
monoxide in patients with copd: a pilot study. Eur Respir J, 30(6):1131–7.
Bauer, B., Goderz, A. L., Braumuller, H., Neudorfl, J. M., Rocken, M., Wieder, T., and Schmalz,
H. G. (2017). Methyl fumarate-derived iron carbonyl complexes (fumet-corms) as powerful
anti-inflammatory agents. ChemMedChem, 12(23):1927–1930.
Bauer, I. and Pannen, B. H. (2009). Bench-to-bedside review: Carbon monoxide–from mito-
chondrial poisoning to therapeutic use. Crit Care, 13(4):220.
Bergstraesser, C., Hoeger, S., Song, H., Ermantraut, L., Hottenrot, M., Czymai, T., Schmidt,
M., Goebeler, M., Ponelies, N., Stich, C., Loesel, R., Molema, G., Seelen, M., van Son, W.,
Yard, B. A., and Rafat, N. (2012). Inhibition of vcam-1 expression in endothelial cells by
corm-3: the role of the ubiquitin-proteasome system, p38, and mitochondrial respiration. Free
Radic Biol Med, 52(4):794–802.
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72:248–54.
59
Bibliography
Brouard, S., Otterbein, L. E., Anrather, J., Tobiasch, E., Bach, F. H., Choi, A. M., and Soares,
M. P. (2000). Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell
apoptosis. J Exp Med, 192(7):1015–26.
Brusko, T. M., Wasserfall, C. H., Agarwal, A., Kapturczak, M. H., and Atkinson, M. A. (2005).
An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance
by cd4+cd25+ regulatory t cells. J Immunol, 174(9):5181–6.
Cabantchik, Z. I. (2014). Labile iron in cells and body fluids: physiology, pathology, and
pharmacology. Front Pharmacol, 5:45.
Cairo, G. and Recalcati, S. (2007). Iron-regulatory proteins: molecular biology and pathophysio-
logical implications. Expert Rev Mol Med, 9(33):1–13.
Campolo, M., Esposito, E., Ahmad, A., Di Paola, R., Wallace, J. L., and Cuzzocrea, S. (2013).
A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from
experimental spinal cord injury. FASEB J, 27(11):4489–99.
Caumartin, Y., Stephen, J., Deng, J. P., Lian, D., Lan, Z., Liu, W., Garcia, B., Jevnikar, A. M.,
Wang, H., Cepinskas, G., and Luke, P. P. (2011). Carbon monoxide-releasing molecules protect
against ischemia-reperfusion injury during kidney transplantation. Kidney Int, 79(10):1080–9.
Chi, P. L., Lin, C. C., Chen, Y. W., Hsiao, L. D., and Yang, C. M. (2015). Co induces
nrf2-dependent heme oxygenase-1 transcription by cooperating with sp1 and c-jun in rat brain
astrocytes. Mol Neurobiol, 52(1):277–92.
Cicala, C., Ianaro, A., Fiorucci, S., Calignano, A., Bucci, M., Gerli, R., Santucci, L., Wallace, J. L.,
and Cirino, G. (2000). No-naproxen modulates inflammation, nociception and downregulates
t cell response in rat freund’s adjuvant arthritis. Br J Pharmacol, 130(6):1399–405.
Coburn, R. F. (1970). The carbon monoxide body stores. Ann N Y Acad Sci, 174(1):11–22.
Coburn, R. F., Blakemore, W. S., and Forster, R. E. (1963). Endogenous carbon monoxide
production in man. J Clin Invest, 42:1172–8.
Derbyshire, E. R. and Marletta, M. A. (2012). Structure and regulation of soluble guanylate
cyclase. Annu Rev Biochem, 81:533–59.
Dief, A. E., Mostafa, D. K., Sharara, G. M., and Zeitoun, T. H. (2015). Hydrogen sulfide releasing
naproxen offers better anti-inflammatory and chondroprotective effect relative to naproxen in
a rat model of zymosan induced arthritis. Eur Rev Med Pharmacol Sci, 19(8):1537–46.
Feng, W., Liu, D., Feng, S., and Feng, G. (2016). Readily available fluorescent probe for carbon
monoxide imaging in living cells. Anal Chem, 88(21):10648–10653.
Fiorucci, S., Antonelli, E., Distrutti, E., Rizzo, G., Mencarelli, A., Orlandi, S., Zanardo, R., Renga,
B., Di Sante, M., Morelli, A., Cirino, G., and Wallace, J. L. (2005). Inhibition of hydrogen
sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs.
Gastroenterology, 129(4):1210–24.
Fiorucci, S. and Distrutti, E. (2011). Coxibs, cinods and h(2)s-releasing nsaids: current
perspectives in the development of safer non steroidal anti-inflammatory drugs. Curr Med
Chem, 18(23):3494–505.
60
Bibliography
Foresti, R., Bani-Hani, M. G., and Motterlini, R. (2008). Use of carbon monoxide as a therapeutic
agent: promises and challenges. Intensive Care Med, 34(4):649–58.
Foresti, R., Hammad, J., Clark, J. E., Johnson, T. R., Mann, B. E., Friebe, A., Green, C. J.,
and Motterlini, R. (2004). Vasoactive properties of corm-3, a novel water-soluble carbon
monoxide-releasing molecule. Br J Pharmacol, 142(3):453–60.
Garcia-Gallego, S. and Bernardes, G. J. (2014). Carbon-monoxide-releasing molecules for the
delivery of therapeutic co in vivo. Angew Chem Int Ed Engl, 53(37):9712–21.
Gilmore, T. D. (2006). Introduction to nf-kappab: players, pathways, perspectives. Oncogene,
25(51):6680–4.
Gonzales, M. A. and Mascharak, P. K. (2014). Photoactive metal carbonyl complexes as potential
agents for targeted co delivery. J Inorg Biochem, 133:127–35.
Gonzales, S., Erario, M. A., and Tomaro, M. L. (2002). Heme oxygenase-1 induction and
dependent increase in ferritin. a protective antioxidant stratagem in hemin-treated rat brain.
Dev Neurosci, 24(2-3):161–8.
Greenberg, G. R. and Wintrobe, M. M. (1946). A labile iron pool. J Biol Chem, 165(1):397.
Gullotta, F., di Masi, A., Coletta, M., and Ascenzi, P. (2012). Co metabolism, sensing, and
signaling. Biofactors, 38(1):1–13.
Hayden, M. S., West, A. P., and Ghosh, S. (2006). Nf-kappab and the immune response.
Oncogene, 25(51):6758–80.
Heinemann, S. H., Hoshi, T., Westerhausen, M., and Schiller, A. (2014). Carbon monoxide–
physiology, detection and controlled release. Chem Commun (Camb), 50(28):3644–60.
Hentze, M. W., Muckenthaler, M. U., Galy, B., and Camaschella, C. (2010). Two to tango:
regulation of mammalian iron metabolism. Cell, 142(1):24–38.
Herrera, B. S., Coimbra, L. S., da Silva, A. R., Teixeira, S. A., Costa, S. K., Wallace, J. L.,
Spolidorio, L. C., and Muscara, M. N. (2015). The h2s-releasing naproxen derivative, atb-346,
inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis. Med
Gas Res, 5:4.
Hervera, A., Leanez, S., Motterlini, R., and Pol, O. (2013). Treatment with carbon monoxide-
releasing molecules and an ho-1 inducer enhances the effects and expression of micro-opioid
receptors during neuropathic pain. Anesthesiology, 118(5):1180–97.
Inaba, H., Fujita, K., and Ueno, T. (2015). Design of biomaterials for intracellular delivery of
carbon monoxide. Biomater Sci.
Inguaggiato, P., Gonzalez-Michaca, L., Croatt, A. J., Haggard, J. J., Alam, J., and Nath, K. A.
(2001). Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance
to apoptosis. Kidney Int, 60(6):2181–91.
Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S., and Yamamoto,
M. (2000). Transcription factor nrf2 coordinately regulates a group of oxidative stress-inducible
genes in macrophages. J Biol Chem, 275(21):16023–9.
61
Bibliography
Jacobs, A. (1976). An intracellular transit iron pool. Ciba Found Symp, (51):91–106.
Jacobs, D., Watt, G. D., Frankel, R. B., and Papaefthymiou, G. C. (1989). Fe2+ binding to apo
and holo mammalian ferritin. Biochemistry, 28(23):9216–21.
Johansen, D., Ytrehus, K., and Baxter, G. F. (2006). Exogenous hydrogen sulfide (h2s) protects
against regional myocardial ischemia-reperfusion injury–evidence for a role of k atp channels.
Basic Res Cardiol, 101(1):53–60.
Johnson, R. A., Kozma, F., and Colombari, E. (1999). Carbon monoxide: from toxin to
endogenous modulator of cardiovascular functions. Braz J Med Biol Res, 32(1):1–14.
Kakhlon, O. and Cabantchik, Z. I. (2002). The labile iron pool: characterization, measurement,
and participation in cellular processes(1). Free Radic Biol Med, 33(8):1037–46.
Katada, K., Bihari, A., Mizuguchi, S., Yoshida, N., Yoshikawa, T., Fraser, D. D., Potter,
R. F., and Cepinskas, G. (2010). Carbon monoxide liberated from co-releasing molecule
(corm-2) attenuates ischemia/reperfusion (i/r)-induced inflammation in the small intestine.
Inflammation, 33(2):92–100.
Kautz, A. C., Kunz, P. C., and Janiak, C. (2016). Co-releasing molecule (corm) conjugate
systems. Dalton Trans, 45(45):18045–18063.
Ke, B., Shen, X. D., Zhai, Y., Gao, F., Busuttil, R. W., Volk, H. D., and Kupiec-Weglinski,
J. W. (2002). Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects
of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther, 13(15):1845–57.
Kim, H. J., Zheng, M., Kim, S. K., Cho, J. J., Shin, C. H., Joe, Y., and Chung, H. T. (2011).
Co/ho-1 induces nqo-1 expression via nrf2 activation. Immune Netw, 11(6):376–82.
Kohmoto, J., Nakao, A., Kaizu, T., Tsung, A., Ikeda, A., Tomiyama, K., Billiar, T. R., Choi,
A. M., Murase, N., and McCurry, K. R. (2006). Low-dose carbon monoxide inhalation prevents
ischemia/reperfusion injury of transplanted rat lung grafts. Surgery, 140(2):179–85.
Kohmoto, J., Nakao, A., Sugimoto, R., Wang, Y., Zhan, J., Ueda, H., and McCurry, K. R. (2008).
Carbon monoxide-saturated preservation solution protects lung grafts from ischemia-reperfusion
injury. J Thorac Cardiovasc Surg, 136(4):1067–75.
Kruszewski, M. (2003). Labile iron pool: the main determinant of cellular response to oxidative
stress. Mutat Res, 531(1-2):81–92.
Kruszewski, M. (2004). The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol,
51(2):471–80.
Lee, B. S., Heo, J., Kim, Y. M., Shim, S. M., Pae, H. O., and Chung, H. T. (2006). Carbon
monoxide mediates heme oxygenase 1 induction via nrf2 activation in hepatoma cells. Biochem
Biophys Res Commun, 343(3):965–72.
Li, Y., Wang, X., Yang, J., Xie, X., Li, M., Niu, J., Tong, L., and Tang, B. (2016). Fluorescent
probe based on azobenzene-cyclopalladium for the selective imaging of endogenous carbon
monoxide under hypoxia conditions. Anal Chem, 88(22):11154–11159.
62
Bibliography
Lo Iacono, L., Boczkowski, J., Zini, R., Salouage, I., Berdeaux, A., Motterlini, R., and Morin, D.
(2011). A carbon monoxide-releasing molecule (corm-3) uncouples mitochondrial respiration
and modulates the production of reactive oxygen species. Free Radic Biol Med, 50(11):1556–
64.
Maines, M. D. (1997). The heme oxygenase system: a regulator of second messenger gases.
Annu Rev Pharmacol Toxicol, 37:517–54.
Mann, B. E. and Motterlini, R. (2007). Co and no in medicine. Chem Commun (Camb),
(41):4197–208.
Marks, G. S., Brien, J. F., Nakatsu, K., and McLaughlin, B. E. (1991). Does carbon monoxide
have a physiological function? Trends Pharmacol Sci, 12(5):185–8.
Masini, E., Vannacci, A., Failli, P., Mastroianni, R., Giannini, L., Vinci, M. C., Uliva, C., Motterlini,
R., and Mannaioni, P. F. (2008). A carbon monoxide-releasing molecule (corm-3) abrogates
polymorphonuclear granulocyte-induced activation of endothelial cells and mast cells. FASEB
J, 22(9):3380–8.
Mayr, F. B., Spiel, A., Leitner, J., Marsik, C., Germann, P., Ullrich, R., Wagner, O., and Jilma,
B. (2005). Effects of carbon monoxide inhalation during experimental endotoxemia in humans.
Am J Respir Crit Care Med, 171(4):354–60.
McCoubrey, W. K., J., Huang, T. J., and Maines, M. D. (1997). Isolation and characterization
of a cdna from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem,
247(2):725–32.
McDonald, L. J. and Murad, F. (1996). Nitric oxide and cyclic gmp signaling. Proc Soc Exp
Biol Med, 211(1):1–6.
Mede, R., Hoffmann, P., Neumann, C., Gorls, H., Schmitt, M., Popp, J., Neugebauer, U., and
Westerhausen, M. (2018). Acetoxymethyl concept for intracellular administration of carbon
monoxide with mn(co)3 -based photocorms. Chemistry, 24(13):3321–3329.
Michel, B. W., Lippert, A. R., and Chang, C. J. (2012). A reaction-based fluorescent probe for
selective imaging of carbon monoxide in living cells using a palladium-mediated carbonylation.
J Am Chem Soc, 134(38):15668–71.
Mizuguchi, S., Capretta, A., Suehiro, S., Nishiyama, N., Luke, P., Potter, R. F., Fraser, D. D.,
and Cepinskas, G. (2010). Carbon monoxide-releasing molecule corm-3 suppresses vascular
endothelial cell sod-1/sod-2 activity while up-regulating the cell surface levels of sod-3 in a
heparin-dependent manner. Free Radic Biol Med, 49(10):1534–41.
Moncada, S. and Higgs, E. A. (1991). Endogenous nitric oxide: physiology, pathology and clinical
relevance. Eur J Clin Invest, 21(4):361–74.
Moncada, S., Palmer, R. M., and Higgs, E. A. (1991). Nitric oxide: physiology, pathophysiology,
and pharmacology. Pharmacol Rev, 43(2):109–42.
Morse, D. and Choi, A. M. (2002). Heme oxygenase-1: the "emerging molecule" has arrived.
Am J Respir Cell Mol Biol, 27(1):8–16.
63
Bibliography
Motterlini, R., Clark, J. E., Foresti, R., Sarathchandra, P., Mann, B. E., and Green, C. J. (2002).
Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities.
Circ Res, 90(2):E17–24.
Motterlini, R., Gonzales, A., Foresti, R., Clark, J. E., Green, C. J., and Winslow, R. M.
(1998). Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute
hypertensive responses in vivo. Circ Res, 83(5):568–77.
Motterlini, R., Haas, B., and Foresti, R. (2012). Emerging concepts on the anti-inflammatory
actions of carbon monoxide-releasing molecules (co-rms). Med Gas Res, 2(1):28.
Motterlini, R., Mann, B. E., and Foresti, R. (2005a). Therapeutic applications of carbon
monoxide-releasing molecules. Expert Opin Investig Drugs, 14(11):1305–18.
Motterlini, R. and Otterbein, L. E. (2010). The therapeutic potential of carbon monoxide. Nat
Rev Drug Discov, 9(9):728–43.
Motterlini, R., Sawle, P., Hammad, J., Bains, S., Alberto, R., Foresti, R., and Green, C. J.
(2005b). Corm-a1: a new pharmacologically active carbon monoxide-releasing molecule.
FASEB J, 19(2):284–6.
Motterlini R, Foresti R, G. C. (2002). Studies on the development of carbon monoxide-releasing
molecules: potential applications for the treatment of cardiovascular dysfunction. Carbon
Monoxide and Cardiovascular Functions, pages 249–271.
Muckenthaler, M. U., Galy, B., and Hentze, M. W. (2008). Systemic iron homeostasis and the
iron-responsive element/iron-regulatory protein (ire/irp) regulatory network. Annu Rev Nutr,
28:197–213.
Murad, F. (1994). Regulation of cytosolic guanylyl cyclase by nitric oxide: the no-cyclic gmp
signal transduction system. Adv Pharmacol, 26:19–33.
Mustafa, A. K., Gadalla, M. M., and Snyder, S. H. (2009). Signaling by gasotransmitters. Sci
Signal, 2(68):re2.
Nakao, A., Faleo, G., Shimizu, H., Nakahira, K., Kohmoto, J., Sugimoto, R., Choi, A. M.,
McCurry, K. R., Takahashi, T., and Murase, N. (2008). Ex vivo carbon monoxide prevents
cytochrome p450 degradation and ischemia/reperfusion injury of kidney grafts. Kidney Int,
74(8):1009–16.
Nakao, A., Huang, C. S., Stolz, D. B., Wang, Y., Franks, J. M., Tochigi, N., Billiar, T. R.,
Toyoda, Y., Tzeng, E., and McCurry, K. R. (2011). Ex vivo carbon monoxide delivery inhibits
intimal hyperplasia in arterialized vein grafts. Cardiovasc Res, 89(2):457–63.
Nakao, A., Kaczorowski, D. J., Wang, Y., Cardinal, J. S., Buchholz, B. M., Sugimoto, R., Tobita,
K., Lee, S., Toyoda, Y., Billiar, T. R., and McCurry, K. R. (2010). Amelioration of rat cardiac
cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Heart
Lung Transplant, 29(5):544–53.
Nakao, A., Toyokawa, H., Tsung, A., Nalesnik, M. A., Stolz, D. B., Kohmoto, J., Ikeda, A.,
Tomiyama, K., Harada, T., Takahashi, T., Yang, R., Fink, M. P., Morita, K., Choi, A. M., and
Murase, N. (2006). Ex vivo application of carbon monoxide in university of wisconsin solution
to prevent intestinal cold ischemia/reperfusion injury. Am J Transplant, 6(10):2243–55.
64
Bibliography
Neto, J. S., Nakao, A., Kimizuka, K., Romanosky, A. J., Stolz, D. B., Uchiyama, T., Nalesnik,
M. A., Otterbein, L. E., and Murase, N. (2004). Protection of transplant-induced renal
ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol, 287(5):F979–
89.
Niesel, J., Pinto, A., Peindy N’Dongo, H. W., Merz, K., Ott, I., Gust, R., and Schatzschneider, U.
(2008). Photoinduced co release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane
(tpm) manganese tricarbonyl complex. Chem Commun (Camb), (15):1798–800.
Otterbein, L. E., Bach, F. H., Alam, J., Soares, M., Tao Lu, H., Wysk, M., Davis, R. J., Flavell,
R. A., and Choi, A. M. (2000). Carbon monoxide has anti-inflammatory effects involving the
mitogen-activated protein kinase pathway. Nat Med, 6(4):422–8.
Otterbein, L. E. and Choi, A. M. (2000). Heme oxygenase: colors of defense against cellular
stress. Am J Physiol Lung Cell Mol Physiol, 279(6):L1029–37.
Otterbein, L. E., Kolls, J. K., Mantell, L. L., Cook, J. L., Alam, J., and Choi, A. M. (1999).
Exogenous administration of heme oxygenase-1 by gene transfer provides protection against
hyperoxia-induced lung injury. J Clin Invest, 103(7):1047–54.
Otterbein, L. E., Soares, M. P., Yamashita, K., and Bach, F. H. (2003a). Heme oxygenase-1:
unleashing the protective properties of heme. Trends Immunol, 24(8):449–55.
Otterbein, L. E., Zuckerbraun, B. S., Haga, M., Liu, F., Song, R., Usheva, A., Stachulak, C.,
Bodyak, N., Smith, R. N., Csizmadia, E., Tyagi, S., Akamatsu, Y., Flavell, R. J., Billiar, T. R.,
Tzeng, E., Bach, F. H., Choi, A. M., and Soares, M. P. (2003b). Carbon monoxide suppresses
arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat
Med, 9(2):183–90.
Pacher, P., Beckman, J. S., and Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and
disease. Physiol Rev, 87(1):315–424.
Pan, T. T., Feng, Z. N., Lee, S. W., Moore, P. K., and Bian, J. S. (2006). Endogenous hydrogen
sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat
ventricular myocytes. J Mol Cell Cardiol, 40(1):119–30.
Pfeiffer, H., Rojas, A., Niesel, J., and Schatzschneider, U. (2009). Sonogashira and "click"
reactions for the n-terminal and side-chain functionalization of peptides with [mn(co)3(tpm)]+-
based co releasing molecules (tpm = tris(pyrazolyl)methane). Dalton Trans, (22):4292–8.
Powell, C. R., Dillon, K. M., and Matson, J. B. (2018). A review of hydrogen sulfide (h2s)
donors: Chemistry and potential therapeutic applications. Biochem Pharmacol, 149:110–123.
Qin, W., Zhang, J., Lv, W., Wang, X., and Sun, B. (2013). Effect of carbon monoxide-releasing
molecules ii-liberated co on suppressing inflammatory response in sepsis by interfering with
nuclear factor kappa b activation. PLoS One, 8(10):e75840.
Rimmer, R. D., Pierri, A. E., and Ford, P. C. (2012). Photochemically activated carbon monoxide
release for biological targets. toward developing air-stable photocorms labilized by visible light.
Coordination Chemistry Reviews, 256(15-16):1509–1519.
65
Bibliography
Rimmer, R. D., Richter, H., and Ford, P. C. (2010). A photochemical precursor for carbon
monoxide release in aerated aqueous media. Inorg Chem, 49(3):1180–5.
Rochette, L., Cottin, Y., Zeller, M., and Vergely, C. (2013). Carbon monoxide: mechanisms of
action and potential clinical implications. Pharmacol Ther, 137(2):133–52.
Romanski, S. (2013). Synthese und Evaluation geschützter oxysubstituierter Dien-Fe(CO) 3
-Komplexe als enzymatisch aktivierbare CO-freisetzende Moleküle (ET-CORMs). Dr. Hut.
Romanski, S., Kraus, B., Guttentag, M., Schlundt, W., Rucker, H., Adler, A., Neudorfl,
J. M., Alberto, R., Amslinger, S., and Schmalz, H. G. (2012). Acyloxybutadiene tricarbonyl
iron complexes as enzyme-triggered co-releasing molecules (et-corms): a structure-activity
relationship study. Dalton Trans, 41(45):13862–75.
Romanski, S., Kraus, B., Schatzschneider, U., Neudorfl, J. M., Amslinger, S., and Schmalz,
H. G. (2011a). Acyloxybutadiene iron tricarbonyl complexes as enzyme-triggered co-releasing
molecules (et-corms). Angew Chem Int Ed Engl, 50(10):2392–6.
Romanski, S., Neudorfl, J. M., and Schmalz, H. G. (2011b). (rs)-tricarbon-yl(eta-1,3-diacet-oxy-
5,5-dimethyl-cyclo-hexa-1,3-diene)iron(0). Acta Crystallogr Sect E Struct Rep Online, 67(Pt
11):m1530.
Romanski, S., Stamellou, E., Jaraba, J. T., Storz, D., Kramer, B. K., Hafner, M., Amslinger, S.,
Schmalz, H. G., and Yard, B. A. (2013). Enzyme-triggered co-releasing molecules (et-corms):
Evaluation of biological activity in relation to their structure. Free Radic Biol Med, 65:78–88.
Romao, C. C., Blattler, W. A., Seixas, J. D., and Bernardes, G. J. (2012). Developing drug
molecules for therapy with carbon monoxide. Chem Soc Rev, 41(9):3571–83.
Rosas, I. O., Goldberg, H. J., Collard, H. R., El-Chemaly, S., Flaherty, K., Hunninghake, G. M.,
Lasky, J. A., Lederer, D. J., Machado, R., Martinez, F. J., Maurer, R., Teller, D., Noth, I.,
Peters, E., Raghu, G., Garcia, J. G. N., and Choi, A. M. K. (2018). A phase ii clinical trial of
low-dose inhaled carbon monoxide in idiopathic pulmonary fibrosis. Chest, 153(1):94–104.
Ryter, S. W. and Choi, A. M. (2009). Heme oxygenase-1/carbon monoxide: from metabolism
to molecular therapy. Am J Respir Cell Mol Biol, 41(3):251–60.
Sandouka, A., Balogun, E., Foresti, R., Mann, B. E., Johnson, T. R., Tayem, Y., Green, C. J.,
Fuller, B., and Motterlini, R. (2005). Carbon monoxide-releasing molecules (co-rms) modulate
respiration in isolated mitochondria. Cell Mol Biol (Noisy-le-grand), 51(4):425–32.
Sarady, J. K., Otterbein, S. L., Liu, F., Otterbein, L. E., and Choi, A. M. (2002). Carbon monoxide
modulates endotoxin-induced production of granulocyte macrophage colony-stimulating factor
in macrophages. Am J Respir Cell Mol Biol, 27(6):739–45.
Sato, K., Balla, J., Otterbein, L., Smith, R. N., Brouard, S., Lin, Y., Csizmadia, E., Sevigny, J.,
Robson, S. C., Vercellotti, G., Choi, A. M., Bach, F. H., and Soares, M. P. (2001). Carbon
monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac
transplants. J Immunol, 166(6):4185–94.
Sawle, P., Foresti, R., Mann, B. E., Johnson, T. R., Green, C. J., and Motterlini, R. (2005).
Carbon monoxide-releasing molecules (co-rms) attenuate the inflammatory response elicited
by lipopolysaccharide in raw264.7 murine macrophages. Br J Pharmacol, 145(6):800–10.
66
Bibliography
Schatzschneider, U. (2010). Photoactivated biological activity of transition metal complexes.
Eur. J. Inorg. Chem, (10):1451–1467.
Schatzschneider, U. (2011). Photocorms: Light-triggered release of carbon monoxide from
the coordination sphere of transition metal complexes for biological applications. Inorganica
Chimica Acta, 374(1):19–23.
Schatzschneider, U. (2015). Novel lead structures and activation mechanisms for co-releasing
molecules (corms). Br J Pharmacol, 172(6):1638–50.
Seldon, M. P., Silva, G., Pejanovic, N., Larsen, R., Gregoire, I. P., Filipe, J., Anrather, J.,
and Soares, M. P. (2007). Heme oxygenase-1 inhibits the expression of adhesion molecules
associated with endothelial cell activation via inhibition of nf-kappab rela phosphorylation at
serine 276. J Immunol, 179(11):7840–51.
Shoman, M. E., DuMond, J. F., Isbell, T. S., Crawford, J. H., Brandon, A., Honovar, J., Vitturi,
D. A., White, C. R., Patel, R. P., and King, S. B. (2011). Acyloxy nitroso compounds as
nitroxyl (hno) donors: kinetics, reactions with thiols, and vasodilation properties. J Med Chem,
54(4):1059–70.
Sitnikov, N. S., Li, Y., Zhang, D., Yard, B., and Schmalz, H. G. (2015). Design, synthesis, and
functional evaluation of co-releasing molecules triggered by penicillin g amidase as a model
protease. Angew Chem Int Ed Engl.
Sjostrand, T. (1951). Endogenous formation of carbon monoxide; the co concentration in the
inspired and expired air of hospital patients. Acta Physiol Scand, 22(2-3):137–41.
Sjostrand, T. (1952a). The formation of carbon monoxide by in vitro decomposition of
haemoglobin in bile pigments. Acta Physiol Scand, 26(4):328–33.
Sjostrand, T. (1952b). The in vitro formation of carbon monoxide in blood. Acta Physiol Scand,
24(4):314–32.
Sodha, N. R., Clements, R. T., Feng, J., Liu, Y., Bianchi, C., Horvath, E. M., Szabo, C.,
Stahl, G. L., and Sellke, F. W. (2009). Hydrogen sulfide therapy attenuates the inflammatory
response in a porcine model of myocardial ischemia/reperfusion injury. J Thorac Cardiovasc
Surg, 138(4):977–84.
Sodha, N. R. and Sellke, F. W. (2015). Attenuation of inflammatory responses by hydrogen
sulfide (h(2)s) in ischemia/reperfusion injury. Methods Enzymol, 555:127–44.
Song, H., Bergstrasser, C., Rafat, N., Hoger, S., Schmidt, M., Endres, N., Goebeler, M.,
Hillebrands, J. L., Brigelius-Flohe, R., Banning, A., Beck, G., Loesel, R., and Yard, B. A.
(2009). The carbon monoxide releasing molecule (corm-3) inhibits expression of vascular
cell adhesion molecule-1 and e-selectin independently of haem oxygenase-1 expression. Br J
Pharmacol, 157(5):769–80.
Song, H., Hoeger, S., Hillebrands, J. L., Mandel, I., Loesel, R., Beck, G., Schilling, L., Schnuelle,
P., and Yard, B. (2010). Corms protect endothelial cells during cold preservation, resulting in
inhibition of intimal hyperplasia after aorta transplantation in rats. Transpl Int, 23(11):1144–53.
67
Bibliography
Song, R., Kubo, M., Morse, D., Zhou, Z., Zhang, X., Dauber, J. H., Fabisiak, J., Alber, S. M.,
Watkins, S. C., Zuckerbraun, B. S., Otterbein, L. E., Ning, W., Oury, T. D., Lee, P. J.,
McCurry, K. R., and Choi, A. M. (2003). Carbon monoxide induces cytoprotection in rat
orthotopic lung transplantation via anti-inflammatory and anti-apoptotic effects. Am J Pathol,
163(1):231–42.
Stamellou, E., Storz, D., Botov, S., Ntasis, E., Wedel, J., Sollazzo, S., Kramer, B. K., van Son,
W., Seelen, M., Schmalz, H. G., Schmidt, A., Hafner, M., and Yard, B. A. (2014). Different
design of enzyme-triggered co-releasing molecules (et-corms) reveals quantitative differences
in biological activities in terms of toxicity and inflammation. Redox Biol, 2:739–48.
Steiger, C., Uchiyama, K., Takagi, T., Mizushima, K., Higashimura, Y., Gutmann, M., Hermann,
C., Botov, S., Schmalz, H. G., Naito, Y., and Meinel, L. (2016). Prevention of colitis by
controlled oral drug delivery of carbon monoxide. J Control Release, 239:128–36.
Stupfel, M. and Bouley, G. (1970). Physiological and biochemical effects on rats and mice
exposed to small concentrations of carbon monoxide for long periods. Ann N Y Acad Sci,
174(1):342–68.
Suematsu, M., Goda, N., Sano, T., Kashiwagi, S., Egawa, T., Shinoda, Y., and Ishimura, Y.
(1995). Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat
liver. J Clin Invest, 96(5):2431–7.
Suematsu, M., Kashiwagi, S., Sano, T., Goda, N., Shinoda, Y., and Ishimura, Y. (1994). Carbon
monoxide as an endogenous modulator of hepatic vascular perfusion. Biochem Biophys Res
Commun, 205(2):1333–7.
Szabo, C. (2007). Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov,
6(11):917–35.
Takagi, T., Uchiyama, K., and Naito, Y. (2015). The therapeutic potential of carbon monoxide
for inflammatory bowel disease. Digestion, 91(1):13–8.
Takahashi, K., Tamagawa, S., Sakano, H., Katagi, T., and Mizuno, N. (1995). Effects of the
ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues. Biol
Pharm Bull, 18(10):1401–4.
Tenhunen, R., Marver, H. S., and Schmid, R. (1968). The enzymatic conversion of heme to
bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A, 61(2):748–55.
Toombs, C. F., Insko, M. A., Wintner, E. A., Deckwerth, T. L., Usansky, H., Jamil, K., Goldstein,
B., Cooreman, M., and Szabo, C. (2010). Detection of exhaled hydrogen sulphide gas in
healthy human volunteers during intravenous administration of sodium sulphide. Br J Clin
Pharmacol, 69(6):626–36.
Tsui, T. Y., Obed, A., Siu, Y. T., Yet, S. F., Prantl, L., Schlitt, H. J., and Fan, S. T. (2007).
Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic
energy metabolism. Shock, 27(2):165–71.
Tsui, T. Y., Siu, Y. T., Schlitt, H. J., and Fan, S. T. (2005). Heme oxygenase-1-derived
carbon monoxide stimulates adenosine triphosphate generation in human hepatocyte. Biochem
Biophys Res Commun, 336(3):898–902.
68
Bibliography
Vadori, M., Seveso, M., Besenzon, F., Bosio, E., Tognato, E., Fante, F., Boldrin, M., Gavasso, S.,
Ravarotto, L., Mann, B. E., Simioni, P., Ancona, E., Motterlini, R., and Cozzi, E. (2009). In
vitro and in vivo effects of the carbon monoxide-releasing molecule, corm-3, in the xenogeneic
pig-to-primate context. Xenotransplantation, 16(2):99–114.
Wagener, F. A., Volk, H. D., Willis, D., Abraham, N. G., Soares, M. P., Adema, G. J., and
Figdor, C. G. (2003). Different faces of the heme-heme oxygenase system in inflammation.
Pharmacol Rev, 55(3):551–71.
Wallace, J. L., Caliendo, G., Santagada, V., and Cirino, G. (2010). Markedly reduced toxicity of
a hydrogen sulphide-releasing derivative of naproxen (atb-346). Br J Pharmacol, 159(6):1236–
46.
Wallace, J. L., Caliendo, G., Santagada, V., Cirino, G., and Fiorucci, S. (2007). Gastrointestinal
safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the
rat. Gastroenterology, 132(1):261–71.
Wang, J., Karpus, J., Zhao, B. S., Luo, Z., Chen, P. R., and He, C. (2012). A selective
fluorescent probe for carbon monoxide imaging in living cells. Angew Chem Int Ed Engl,
51(38):9652–6.
Wang, R. (2002). Two’s company, three’s a crowd: can h2s be the third endogenous gaseous
transmitter? FASEB J, 16(13):1792–8.
Wang, R. (2014). Gasotransmitters: growing pains and joys. Trends Biochem Sci, 39(5):227–32.
Wang, R., Wang, Z., and Wu, L. (1997). Carbon monoxide-induced vasorelaxation and the
underlying mechanisms. Br J Pharmacol, 121(5):927–34.
White, W. B., Schnitzer, T. J., Bakris, G. L., Frayssinet, H., Duquesroix, B., and Weber, M.
(2011). Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol,
107(9):1338–45.
Wu, L. and Wang, R. (2005). Carbon monoxide: endogenous production, physiological functions,
and pharmacological applications. Pharmacol Rev, 57(4):585–630.
Yabluchanskiy, A., Sawle, P., Homer-Vanniasinkam, S., Green, C. J., Foresti, R., and Motterlini,
R. (2012). Corm-3, a carbon monoxide-releasing molecule, alters the inflammatory response
and reduces brain damage in a rat model of hemorrhagic stroke. Crit Care Med, 40(2):544–52.
Yang, L., Quan, S., and Abraham, N. G. (1999). Retrovirus-mediated ho gene transfer into
endothelial cells protects against oxidant-induced injury. Am J Physiol, 277(1 Pt 1):L127–33.
Zanardo, R. C., Brancaleone, V., Distrutti, E., Fiorucci, S., Cirino, G., and Wallace, J. L. (2006).
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J,
20(12):2118–20.
Zobi, F. (2013). Co and co-releasing molecules in medicinal chemistry. Future Med Chem,
5(2):175–88.
Zobi, F., Quaroni, L., Santoro, G., Zlateva, T., Blacque, O., Sarafimov, B., Schaub, M. C., and
Bogdanova, A. Y. (2013). Live-fibroblast ir imaging of a cytoprotective photocorm activated
with visible light. J Med Chem, 56(17):6719–31.
69
Bibliography
Zuckerbraun, B. S., Chin, B. Y., Bilban, M., d’Avila, J. C., Rao, J., Billiar, T. R., and Otterbein,
L. E. (2007). Carbon monoxide signals via inhibition of cytochrome c oxidase and generation
of mitochondrial reactive oxygen species. FASEB J, 21(4):1099–106.
Zuckerbraun, B. S., Chin, B. Y., Wegiel, B., Billiar, T. R., Czsimadia, E., Rao, J., Shimoda, L.,
Ifedigbo, E., Kanno, S., and Otterbein, L. E. (2006). Carbon monoxide reverses established
pulmonary hypertension. J Exp Med, 203(9):2109–19.
70
Curriculum Vitae
Personal information
Name: Dennis Erich Storz
Date of birth: March 22nd 1986
Place of birth: Villingen-Schwenningen, Baden-Württemberg
Marital status: Single
Father: Klaus Storz
Mother: Angelika Kayan
Education
1996 – 2005 Highschool, Gymnasium am Hoptbühl, Villingen-Schwenningen
(Abitur degree)
Social service
2005 – 2006 Civil Service, Nachsorgeklinik Tannheim
2007 – 2012 Voluntary Year of Social Service (FSJ) and Emergency Medical
Assistant, Deutsches Rotes Kreuz Rettungsdienst
Schwarzwald-Baar gGmbH
Academic education
2008 – 2015 Studies of Human Medicine, Medical Faculty Mannheim,
Heidelberg University
10.09.2015 Medical Approbation
2012 – 2018 Doctoral Candidate, Vth Medical Department of Nephrology,
Endocrinology and Rheumatology, Medical Faculty Mannheim,
Heidelberg University
Professional career
2015 Lecturer at Heilpraktikerakademie Wong, Bad Dürkheim
2016 – 2018 Resident at Düsseldorf University Hospital, Department of
General Paediatrics, Neonatology and Paedatric Cardiology
Sept. 2018 to present Professional Diploma in Tropical Medicine and Hygiene at the
London School of Hygiene and Tropical Medicine, United
Kingdom
71
Publications
Peer-reviewed journal articles
Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative
differences in biological activities in terms of toxicity and inflammation.
Stamellou, E.∗, Storz, D.∗, Botov, S., Ntasis, E., Wedel, J., Sollazzo, S., Krämer, B.K., van Son,
W., Seelen, M., Schmalz, H.G., Schmidt, A., Hafner, M., Yard, B.A. (2014). Redox Biology 2:
739-748.
∗SE and SD have contributed equally to this study
Enzyme-triggered CO-releasing molecules (ET-CORMs): Evaluation of biological activity in
relation to their structure.
Romanski, S., Stamellou, E., Jaraba, J.T., Storz, D., Krämer, B.K., Hafner, M., Amslinger, S.,
Schmalz, H.G., Yard, B.A. (2013). Free Radical Biology and Medicine 65: 78-88.
Case reports
Atypical neuroimaging in Wilson’s disease.
Patell, R., Dosi, R., Joshi, H.K., Storz, D. (2014). British Medical Journal Case Reports.
(doi:10.1136/bcr-2013-200100).
Conference contributions
Fever and sacroiliac pain: Think systemic brucellosis!
Winkler, W., Storz, D., Bartelt, J., Urffer, S., Tarr, P.
83. Schweizerische Gesellschaft für Allgemeine Innere Medizin - Jahresversammlung, Basel,
Schweiz (2015).
Splenomegalie, Ösophagusvarizen, Panzytopenie und Koagulopathie - Komplizierter M. Gaucher
oder einfache Pfortaderthrombose?
Storz, D., Thimm, E., Welsch, S., Schaper, J., Esposito, I., Friedt, M.
32. Jahrestagung der Gesellschaft für pädiatrische Gastroenterologie und Ernährung, Alpbach,
Österreich (2017).
72
Acknowledgements
Ich bedanke mich bei Herrn Prof. Dr. rer. nat. Benito A. Yard für die Betreuung bei dieser Arbeit
und die Möglichkeit sie in einem sehr entspannten, gleichzeitig fokussierten und zielstrebigen
Umfeld zu bearbeiten.
Besonderer Dank gilt meiner Betreuerin Eleni Stamellou für die Hilfsbereitschaft, Unterstützung
und Geduld, die mir so häufig entgegenbracht wurde. Ich danke für die vielen Gespräche auf
wissenschaftlicher und persönlicher Ebene, sowie für die wichtigen Diskussionen, die mir zum
tieferen Verständnis der Thematik verhalfen.
Ich danke der gesamten Forschungsgruppe für die Unterstützung während den Experimenten,
die von allen als selbstverständlich angesehen wurde. Im Einzelnen möchte ich Frau Annette
Breedijk, Frau Katharina Prem und Frau Sophie Gärtner besonders für die große technische
Hilfsbereitschaft im Labor danken.
Mein Dank gilt ebenso den wissenschaftlichen Kollegen Prama Pallavi, Johannes Wedel und
Emmanouil Ntasis für den bereichernden, konstruktiven Austausch und die angenehme Zusam-
menarbeit.
Auch über die wissenschaftliche Arbeit hinaus danke ich meinen engsten Freunden für die endlose
moralische Unterstützung und den Rückenwind. Ausdrücklich danke ich dabei Mathias Davids, der
mich gerade gegen Ende insbesondere fachlich und technisch unterstütz hat, dieser Dissertation
den letzten Schliff zu geben.
Außerdem danke ich meiner Familie für ihr großes Verständnis während der gesamten Arbeit und
besonders Kim und Moaz Bajwa für das detaillierte Korrekturlesen. Zu guter Letzt danke ich
meiner Mutter Angelika Kayan, meinem Vater Klaus Storz und meinem Stiefvater Günter Kayan
für ihren unverzichtbaren, nie endenden Rückhalt.
73
